Auszug
Auf dem Hintergrund breiter klinischer Erfahrung, empirischer Forschungsergebnisse und stringenter Resultate aus der Grundlagenforschung in den letzten 15 Jahren zeichnen sich inzwischen konstruktvalide Modelle zum komplementären Bedingungsgefüge in der Entstehung und Aufrechterhaltung süchtiger Verhaltenspathologie ab. Die auf unterschiedlichen Untersuchungs- und Funktionsebenen gewonnenen Forschungsergebnisse bestätigen, dass die individuelle Vulnerabilität für eine stoffliche wie nichtstoffgebundene Abhängigkeitserkrankung gleichermaßen durch (neuro-)biologische, verhaltenspsychologische und soziale Kontextvariablen bestimmt wird. Suchtstoffspezifische und nosologieübergreifend unspezifische genetische Einflussfaktoren vor und während der Abhängigkeitsentwicklung gehören ebenso dazu wie manifestationsfördernde Umweltbedingungen der individuellen Lebensgeschichte.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
ABI-DARGHAM A, KRYSTAL JH, ANJILVEL S et al. (1998) Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123l] iomazenil. Am J Psychiatry 155: 1550–1555
AGARWAL DP, GOEDDE HW (1992) Pharmacogenetics of alcohol metabolism and alcoholism. Pharmacogenetics 2: 48–62
AGGLETON, JP, MISHIN M (1986) The amygdala: sensory gateway to the emotions. In: Plutchik R, Kellermann H (eds) Emotion theory, research and experience, vol 3. Academic Press, Orlando
Alexander GE, De Long MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 9: 357–381
Baxter LR, Phleps ME, Mazziotta JC et al. (1987) Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Arch Gen Psychiatry 44: 211–218
BEGLEITER H, PORJESZ B, REICH T et al. (1998) Quantitative trait loci analysis of human event-related brain potentials: P3 voltage. Electroencephal Neurophysiol 108: 244–250
Benjamin J, Li L, Patterson C (1996) Population and family association between the dopamine receptor gene and novelty seeking. Nat Genet 12: 81–84
Biederman J, Faraone S, Milberger S et al. (1996) Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 35: 343–351
Biederman J, Wilens TE, Mick E et al. (1998) Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry 44: 269–273
Biederman J, Mick E, Faraone SV (2000) Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 157: 816–818
Birbaumer N, Jänig W (1997) Motivation and Emotion. In: Schmidt RF, Thews G (Hrsg) Physiologie des Menschen. Springer, Berlin Heidelberg New York Tokyo, S 167–183
Birbaumer N, Schmidt TRF (1999) Biologische Psychologie, 4. Aufl. Springer, Berlin Heidelberg New York Tokyo, S 566
Blum K, Cull JG, Braverman ER et al. (1996) Reward deficiency syndrome. Am Sci 84: 132–145
Böning J (1991) Zur Neurobiologie und Psychopathologie süchtigen Verhaltens. In: Wanke K, Bühringer G (Hrsg) Grundstörungen der Sucht. Springer, Berlin Heidelberg New York Tokyo, S 1–27
Böning J (1994) Warum muß es ein „Suchtgedächtnis“ geben? Klinische Empirie und neurobiologische Argumente. Sucht 40: 244–252
Böning J (2000) Zur Neuropsychobiologie und Klinik des „Suchtgedächtnisses“. In: Stetter F (Hrsg) Suchttherapie an der Schwelle der Jahrtausendwende. Neuland, Geesthacht, S 37–50
Böning J (2001) Neurobiology of an addiction memory. J Neural Transm 108: 755–756
Böning J, Weijers HG, Herrmann MJ (2002) Suchtgedächtnis und Cue-Reaktivität — eine neuropsychobiologische Synopsis. Psychomed 14: 74–80
Bonson KR, Grant SJ, Contoreggi CS et al. (2002) Neural systems and cue-induced cocaine craving. Neuropsychopharmacol 26: 376–386
Bottlender M, Soyka M (2005) The impact of different personality dimensions (NEO-FFI) on the outcome of alcohol-dependent patents six and twelve months after treatment. Psychiatry Res (in press)
Buchholz KK, Hesselbrock VM, Heath AC et al. (2000) A latent class analysis of antisocial personality disorder symptom data from a multi-centre family study of alcoholism. Addiction 95: 553–567
Cantor-Graae E, Nordstrom LG, McNeil TF (2001) Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 48: 69–82
Christiansen KO (1974) The genesis of aggressive criminality. Implications of a study of crime in a Danish twin study. In: Dewit J, Hartup WW (eds) Determinants and origin of aggressive behaviour. Mouton, The Hague
Cloninger CR (1987) Neurogenetic adaptive mechanisms in alcoholism. Science 236: 410–416
Cloninger CR, Sigvardsson S, Bohman M (1988) Childhood personality predicts alcohol abuse in young adults. Alcohol Clin Exp Res 4: 494–505
Collingridge GL, Davies SN (1989) NMDA receptors and long-term potentiation in the hippocampus. In: Watkins JC, Collingridge GL (eds) The NMDA receptor. IRL Press, Oxford, pp 123–136
Comings DE (2001) Clinical and molecular genetics of ADHD and Tourette syndrome. Two related polygenic disorders. Ann NY Acad Sci 931: 50
Conrad K (1963) (Hrsg) Der Konstitutionstypus, 2. Aufl. Springer, Berlin Göttingen Heidelberg
Dalgaard OS, Kringelen E (1976) A Norwegian study of criminality. Br J Criminol 16: 13–232
Deissler K (1977) Der periodische Suchtanfall. Schweiz Ärztetag 13: 514–517
de Mendelssohn A, Kaspar S, Tauscher J (2004) Neuroimaging bei Substanzabhängigkeit. Nervenarzt 75: 651–662
Dervaux A, Bayle FJ, Laqueille X et al. (2001) Is substance abuse in schizophrenia related to impulsivity, sensation seeking, or anhedonia? Am J Psychiatry 158: 492–494
di Chiara G (1995) The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alc Depend 38: 95–137
Donovan JM (1986) An etiologic model of alcoholism. Am J Psychiatry 143: 1–11
Dulawa SC, Grandy DK, Low MJ et al. (1999) Dopamine D4 receptor-knock-out-mice exhibit reduced exploration of novel stimuli. J Neurosci 19: 955–956
Duke PJ, Pantelis C, Mcphillips MA et al. (2001) Comorbid non-alcohol substance misuses among people with schizophrenia: epidemiological study in central London. Br J Psychiatry 179: 509–513
Ebstein RP, Nowick O, Umansky R (1996) Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. Nat Genet 12: 78–80
Ebstein RP, Segman R, Benjamin J et al. (1997) 5-HT2C (HTR2C) serotinin receptor gene polymorphism associated with the human personality trait of reward dependence: interaction with dopamine D4 receptor (D4DR) and dopamine D3 receptor (D3DR) polymorphisms. Am J Med Genet 74: 65–72
Emrich HM (1989) A three-component-system hypothesis of psychosis. Impairment of binocular depth inversion as an indicator of a functional dysequilibrium. Br J Psychiatry 155[Suppl 5]: 37–39
Enoch MA, Goldman D (1999) Genetics of alcoholism and substance abuse. Psychiatr Clin North Am 22: 289–299
Fallgatter AJ, Wiesbeck GA, Weijers HG et al. (1998) Event-related correlates of response suppression as indicators of novelty seeking in alcoholics. Alcoholism 33: 475–481
Faraone SV, Doyle AE, Mick E et al. (2001) Metaanalysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperactivity disorder. Am J Psychiatry 158: 1052–1057
Foroud T, Buchholz KK, Edenberg HJ et al. (1998) Linkage of an alcoholism-related severity phenotype to chromosome 16. Alcohol Clin Exp Res 22: 2035–2042
Foroud T, Edenberg HJ, Goate A et al. (2000) Alcoholism susceptibility loci: confirmation studies in a replicate sample and further mapping. Alcohol Clin Exp Res 24: 993–945
Goldstein A (1989) (ed) Molecular and cellular aspects of the drug addictions. Springer, Berlin Heidelberg New York
Goldstein RZ, Volkow ND (2002) Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159: 1642–1652
Gottesmann II, Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160: 636–645
Gouzoulis-Mayfrank E (2004) Doppeldiagnose Psychose und Sucht. Nervenarzt 75: 642–650
Grant S, Lond ED, Newlin DB et al. (1996) Activation of memory circuits during cue-elicited cocaine craving. Proc Natl Acad Sci USA 93: 12040–12045
Gray JA, Rawlins JNP (1986) Comparator and buffer memory: an attempt to integrate two models of hippocampal functions. In: Isaacson RL, Pribram KH (eds) The hippocampus. Plenum, New York, pp 159–201
Grüsser S, Wölfling K, Heinz A (2002) Sucht, Verlangen und lerntheoretische Erklärungsansätze zur Entstehung und Aufrechterhaltung von süchtigem Verhalten. Psychomed 14: 68–73
Haenschel C, Baldeweg T, Croft RJ et al. (2002) Gamma and beta frequency oscillations in response to novel auditory stimuli: a comparison of human electroencephalogram (EEG) data with in vitro models. Proc Natl Acad Sci USA 97: 7645–7650
Hartka E, Johnstone B, Leino EV et al. (1991) The collaborative alcohol-related longitudinal project: a meta-analysis of depressive symptomatology and alcohol consumption over time. Br J Addict 86: 1283–1298
Heath AC, Buchholz KK, Madden PA et al. (1997) Genetic and environmental contributions to alcohol dependence risk in a national twin sample: consistency of findings in women and men. Psychol Med 27: 1381–1396
Heinz A (1999a) Anthropological and neurobiological aspects of compulsions and rituals. Pharmacopsychiatry 32: 223–229
Heinz A (1999b) Neurobiological and anthropological aspects of compulsions and rituals. Pharmacopsychiatry 32: 1–7
Heinz A (1999c) Anhedonie — nosologieübergreifendes Korrelat einer Dysfunktion des dopaminergen Verstärkungssystems? Nervenarzt 70: 391–398
Heinz A, Batra A (2003) Neurobiologie der Alkohol-und Nikotinabhängigkeit. Kohlhammer, Stuttgart
Heinz A, Higley JD, Gorey JG et al. (1998a) In vivo association between alcohol intoxication, aggression, and serotonin transporter availability in nonhuman primates. Am J Psychiatry 155: 1023–1028
Heinz A, Ragan P, Jones DW et al. (1998b) Reduced serotonin transporters in alcoholism. Am J Psychiatry 155: 1544–1549
Heinz A, Reinold M, Wrase J et al. (2005) Stable elevations in striatal μ-opioid receptor availability in detoxified alcoholics correlate with alcohol craving — a [11C] Carfentanil PET study. Gen Arch Psychiatry 62: 57–64
Herrmann MJ, Sonnek G, Weijers H-G et al. (2002) Intensity dependence of auditory evoked potentials and the personality dimension “harm avoidance” in alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 26: 127–161
Hesselbrock V, Begleiter H, Porjesz B et al. (2001) P 300 event-related potential amplitude as an endophenotype of alcoholism — evidence from the collaborative study on the genetics of alcoholism. J Biomed Sci 8: 77–82
Heyne A, May T, Goll P et al. (2000) Persisting consequences of drug intake: towards a memory of addiction. J Neural Transm 107: 613–638
Holzberg D, Albrecht U (2003) The circadian clock: a manager of biochemical processes within the organism. J Neuroendocrinol 15: 339–343
Hosák L, Preiss M, Halíř M et al. (2004) Temperament and character inventory (TCI) personality profile in metamphetamine abusers: a controlled study. Eur Psychiatry 19: 193–195
Jacobs EH, Spijker S, Verhoog CW et al. (2002) Active heroin administration induces specific genomic responses in the nucleus accumbens shell. FASEB J 16: 1961–1963
Johann M, Bobbe G, Putzhammer A et al. (2003) Comorbidity of alcohol dependence with attention-deficit hyperactivity disorder: differences in phenotype with increased severity of the substance disorder, but not in genotype (serotonin transporter, 5-HT2C receptor). Alcohol Clin Exp Res 27: 1527–1534
Johnson EO, van der Bree MB, Pickens RW (1996) Subtypes of alcohol-dependent men: a typology based on relative genetic and environmental loading. Alcohol Clin Exp Res 20: 1472–1480
Kampe H, Kunz D, Overbeck-Larisch M et al. (1996) Die Bedeutung des Sondersprachgebrauchs Drogenabhängiger für das Erleben und Verhalten. Sucht 43: 18–36
Kendler KS, Neale MC, Heath AC et al. (1994) A twin-family study of alcoholism in women. Am J Psychiatry 151: 707–715
Kendler KS, Neale MC, Sullivan P et al. (1999) A population-based twin study in women of smoking initiation and nicotine dependence. Psychol Med 29: 299–308
Knop J (1985) Premorbid assessment of young men at high risk for alcoholism. In: Galanter M (ed) Recent developments in alcoholism, vol III. Plenum Press, New York London, pp 53–64
Knorring AL V, Bohmann M, Knorring L V et al. (1985) Platelet MAO activity as a biological marker in subgroups of alcoholism. Acta Psychiatr Scand 72: 51–58
Krause R (1983) Zur Onto-und Phylogenese des Affektsystems und ihrer Beziehungen zu psychischen Störungen. Psyche 11: 1016–1043
Ledoux JE (1999) Das Gedächtnis für Angst. Spektrum der Wissenschaft: 16–23
Lee MA, Meltzer HY (2001) Substance abuse in schizophrenia. Biological factors mediating comorbidity and the potential role of atypical antipsychotic drugs. In: Hubbard JR, Martin PR (eds) Substance abuse in the mentally and physically disabled. Marcel Dekker, New York, pp 77–101
Lesch KP, Bengel D, Heils A et al. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527–1531
Leshner A (1997) Addiction is a brain disease, and it matters. Science 278: 45–47
Lörch B (2002) Alkoholverlangen und dessen klinische Bedeutsamkeit. Psychomed 14: 92–97
Maier W (1996) Genetik von Alkoholabusus aund Alkoholabhängigkeit. In: Mann K, Buchkremer G (Hrsg) Sucht-Grundlagen. Diagnostik, Therapie. Fischer, Stuttgart Jena New York, S 85–97
Maier W (2004) Genetische und Umweltfaktoren bei der Entstehung von Suchterkrankungen. Vortrag, 15. Wissenschaftliche Tagung, Deutsche Gesellschaft für Suchtforschung und Suchttherapie, Essen, 2. April 2004 (unveröffentlicht)
Markowitsch HJ (1999) (Hrsg) Gedächtnisstörungen. Kohlhammer, Stuttgart Berlin Köln
Melichar JK, Daglish MR, Nutt DJ (2001) Addiction and withdrawal-current views. Curr Opin Pharmacol 1: 84–90
Milberger S, Biedermann J, Faraone SV et al. (1997) Associations between ADHD and psychoactive substance use disorders. Findings from a longitudinal study of high-risk siblings of ADHD children. Am J Addict 6: 318–329
Morris RGM, Davis S, Butcher SP (1989) The role of NMDA receptors in learning and memory. In: Watkins JC, Collingridge GL (eds) The NMDA receptor. IRL Press, Oxford New York Tokyo, pp 241–268
Mueser KT, Yarnold PR, Rosenberg SD et al. (2000) Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups. Schizophr Bull 26: 179–192
Mumford D (1991) On the computational architecture of the neocortex. Biol Cybern 65: 133–145
Naber PA, Witter MP, Lopes Silva FH (2000) Networks of the hippocampal memory system of the rat. The pivotal role of the subiculum. Ann NY Acad Sci 911: 392–403
Netter P, Rammsayer T (1991) Reactivity to dopaminergic drugs and aggression related personality traits. Pers Ind Diff 12: 1009–1017
O’brien CP, Childress AR, Ehrmann RN et al. (1998) Conditioning factors in drug abuse: can they explain compulsion? J Psychopharmacol 12: 15–22
Osier MV, Pakstis AJ, Soodyall H et al. (2002) A global perspective on genetic variation at the ADH genes reveals unusual patterns of linkage disequilibrium and diversity. Am J Hum Genet 71: 84–99
Papousek H, Papousek M, Giese R (1986) Neue wissenschaftliche Ansätze zum Verständnis der Mutter-Kind Beziehung. In: Stork J (Hrsg) Zur Psychologie und Psychopathologie des Säuglings. Fromman-Holzboog, Stuttgart, S 53–71
Paulus MP, Hozack NE, Zauscher BE et al. (2002) Behavioral and functional neuroimaging evidence for prefrontal dysfunction in metamphetamine-dependent subjects. Neuropsychopharmacology 26: 53–63
Pihl RO, Finn P, Peterson J (1989) Autonomic hyperreactivityand risk for alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 13: 489–496
Ploog D (1986) Zur Psychopathologie der Emotionen unter neuroethologischem Aspekt. In: Heimann H, Gaertner HJ (Hrsg) Das Verhältnis der Psychiatrie zu ihren Nachbardisziplinen. Springer, Berlin Heidelberg New York, S 15–31
Pollock VE, Gabrielli WF, Mednick SA et al. (1988) EEG identification of subgroups of men at risk for alcoholism? Psychiatry Res 26: 101–114
Porjesz B, Almasy L, Edenberg HJ et al. (2002) Linkage disequilibrium between the beta frequency of the human EEG and a GABAA receptor gene locus. Proc Natl Acad Sci USA 99: 3729–3733
Pritzel M, Brand M, Markowitsch AJ (2003) Gehirn und Verhalten. Spektrum, Heidelberg Berlin
Reich T, Edenberg HJ, Goate A et al. (1998) Genome-wide search for genes affecting the risk for alcohol dependence. Am J Med Genet 81: 207–215
Risch NJ (2000) Searching for genetic determinants in the new millennium. Nature 405: 847–856
Robbins SJ, Ehrmann RN (1992) Designing studies of drug conditioning in humans. Psychopharmacology 106: 143–153
Robbins TW (2002) ADHD and addiction. Nat Med 8: 24–25
Robinson TE, Kolb B (1997) Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J Neurosci 17: 8491–8497
Routtenberg O (1988) Das Belohnungssystem des Gehirns. In: Spektrum der Wissenschaft. Gehirn und Nervensystem. Verlagsgemeinschaft Weinheim, Heidelberg, S 161–167
Saccone NL, Kwon JM, Corbett J et al. (2000) A genome screen of maximum number of drinks as an alcoholism phenotype. Am J Med Genet 96: 632–637
Samochowiec J, Kucharska-Mazur J, Rybakowski F et al. (2002) Norepinephrine transporter polymorphism and personality trait of reward dependence in male alcoholics. Pharmacopsychiatry 35: 195–196
Sandkühler J (2000) Learning and memory in pain pathways. Pain 88: 113–118
Schiffelholz T, Aldenhoff J (2001) Neuronale Plastizität — das Geheimnis der Gedächtnisbildung? Nervenheilkunde 20: 189–193
Schrappe O (1978) Abhängigkeit — Symptom oder Krankheit? In: Keup W (Hrsg) Sucht als Symptom. Thieme, Stuttgart, S 29–37
Schrappe O (1980) Toxikomanie. In: Peters UH (Hrsg) Die Psychologie des 20. Jahrhunderts, Bd X. Ergebnisse für die Medizin. 2. Psychiatrie. Kindler, Zürich, S 849–868
Schuckit MA (1984) Subjective responses to alcohol in sons of alcoholics and control subjects. Arch Gen Psychiatry 41: 879–884
Schuckit MA (1985) The clinical implications of primary diagnostic groups among alcoholics. Arch Gen Psychiatry 42: 1043–1049
Schuckit MA (1994a) A clinical model of genetic influences in alcohol dependence. J Stud Alcohol 55: 5–17
Schuckit MA (1994b) Low level of response as a predictor of future alcoholism. Am J Psychiatry 151: 184–189
Schuckit MA (1996) Auf der Suche nach Prädiktoren für die Entwicklung einer Alkoholabhängigkeit: eine prospektive Studie. In: Mann K, Buchkremer G (Hrsg) Sucht — Grundlagen, Diagnostik, Therapie. Fischer, Stuttgart Jena New York, S 107–117
Schuckit MA (1998) Biological, psychological and environmental predictors of alcoholism risk: a longitudinal study. J Stud Alcohol 59: 485–494
Schuckit MA, Smith TL (1996) An 8-year follow-up of 450 sons of alcoholics and control subjects. Arch Gen Psychiatry 53: 202–210
Schuckit MA, Smith TL (2000) The relationships of a family history of alcohol dependence, a low level of response to alcohol and six domains of life functioning to the development of alcohol use disorders. J Stud Alcohol 61: 827–835
Schuckit MA, Smith TL (2001) The clinical course of alcohol dependence associated with a low level of response to alcohol. Addiction 96: 903–910
Schuckit MA, Smith TL (2004) Changes over time in the self-reported level of response to alcohol. Alcoholism 39: 433–438
Schuckit MA, Smith TL, Tipp JE (1997) The self-rating of the effects of alcohol (SRE) form as a retrospective measure of the risk for alcoholism. Addiction 92: 979–988
Schuckit MA, Mazzanti C, Smith TL et al. (1999) Selective genotyping for the role of the 5-HT2A, 5-HT2C and GABAα6 receptors and the serotonin transporter in the level of response to alcohol. A pilot study. Biol Psychiatry 45: 647–651
Schuckit MA, Smith TL, Kalmijn J et al. (2000) Response to alcohol in daughters of alcoholics: a pilot study and a comparison with sons of alcoholics. Alcoholism 35: 242–248
Schuckit MA, Edenberg HJ, Kalmijn J et al. (2001) Genome-wide Search for genes that relate to a low level of response to alcohol. Alcohol Clin Exp Res 25: 323–329
Schuckit MA, Smith TL, Danko GP et al. (2003) Level of response to alcohol measured on the self-rating of the effects of alcohol questionnaire in a group of 40-year-old women. Am J Drug Alcohol Abuse 29: 191–201
Schumann G (2004) Genetic analysis of glutamatergic signaling genes in alcohol dependence. Alcohol Clin Exp Res 28[Suppl]: 72A
Schumann G, Spanagel R, Mann K (2003a) Candidate genes for alcohol dependence: animal studies. Alcohol Clin Exp Res 27: 880–888
Schumann G, Rujescu D, Kissling C et al. (2003b) Analysis of genetic variations of protein tyrosine kinase fyn and their association with alcohol dependence in two independent cohorts. Biol Psychiatry 54: 1422–1426
Smalley SL, Bailey JN, Palmer CG et al. (1998) Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit hyperactivity disorder. Mol Psychiatry 3: 427–430
Spanagel R (2001) Gibt es ein Drogen-und Suchtgedächtnis? Hinweise aus tierexperimentellen Untersuchungen. Sucht 47: 365–367
Spanagel R, Pendyala G, Abarca C, et al. (2005) The clock gene Period2 influences the glutamatergic system and thereby modulates alcohol consumption. Nature Med 11: 35–42
Tarter RE, Alterman AL, Edwards KL (1985) Vulnerability to alcoholism in men: a behaviorgenetic perspective. J Stud Alcohol 46: 329–356
Tsai G, Coyle JT (1998) The role of glutamatergic neurotransmission in the patho-physiology of alcoholism. Ann Rev Med 49: 173–184
Tulving E (1995) Organization of memory: quo vadis? In: Gazzaniga NS (ed) The cognitive neurosciences. MIT Press, Cambridge, pp 839–847
Verheul R, van den Brink W, Geerlings P (1999) A three pathway psychobiological model of craving for alcohol. Alcoholism 34: 197–222
Volavka J, Czobor P, Goodwin W et al. (1996) The electroencephalogram after alcohol administration in high-risk men and the development of alcohol use disorders 10 years later. Arch Gen Psychiatry 53: 258–263
Volkow ND, Fowler JS (2000) Addiction, a disease of compulsion and drive: involvement of orbitofrontal cortex. Cereb Cortex 10: 318–325
Volkow ND, Chang L, Wang GJ et al. (2001) Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am J Psychiatry 158: 383–389
Volkow ND, Fowler JS, Wang GJ (2002) Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 13: 355–366
Vorel SR, Liu X, Hayes RJ et al. (2001) Relapse to cocaine-seeking after hippocampal theta burst stimulation. Science 292: 1175–1178
Weijers H-G, Wiesbeck GA, Jakob F et al. (2001) Neuroendocrine response to fenfluramine and its relationship to personality in alcoholism. J Neural Transm 108: 1093–1105
Weijers H-G, Wiesbeck GA, Wodarz N et al. (2003) Gender and personality in alcoholism. Arch Wom Ment Health 6: 245–252
Weijers H-G, Wiesbeck GA, Böning J (2005) Biopsychological personality traits as predictors for relapse in primary alcoholism. Alcohol Clin Exp Res (in press)
Wiesbeck GA (2000) Untersuchungen zum Sensation seeking als Vergleichs-, Prädiktions-und Typisierungsmerkmal bei primärer Alkoholabhängigkeit. Habilitationsschrift, Medizinische Fakultät, Universität Würzburg
Wiesbeck GA, Böning J (1996) Dopaminerge Aktivität und verhaltensbiologische Persönlichkeitsmerkmale Alkoholabhängiger im „drug challenge“ — Paradigma. In: Mann K, Buchkremer G (Hrsg) Sucht — Grundlagen, Diagnostik, Therapie. Fischer, Stuttgart Jena New York, S 67–75
Wiesbeck GA, Mauerer C, Thome J et al. (1996) Sensation seeking, alcoholism and dopamine activity. Eur Psychiatry 11: 87–92
Wiesbeck GA, Müller T, Wodarz N et al. (1998) Growth hormone response to apomorphine and to growth hormone releasing hormone in abstinent alcoholics and control subjects. Drug Alc Depend 52: 53–56
Wiesbeck GA, Weijers H-G, Böning J (1999) Untersuchung zur klinischen Gültigkeit der Typ 1/Typ 2 Differenzierung nach Cloninger bei alkoholabhängigen Männern. Suchtmedizin 1: 27–32
Wiesbeck GA, Weijers H-G, Wodarz N et al. (2004) Serotonin transporter gene polymorphism and personality traits in primary alcohol dependence. World Biol Psychiatry 5: 45–48
Wikler A (1973) Dynamics of drug dependence: implications of a conditioning theory for researchand treatment. Arch Gen Psychiatry 28: 611–616
Wikler A (2004) Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am 27: 283–301
Wise R (1996) Neurobiology of addiction. Curr Opin Neurobiol 6: 243–251
Wodarz N (2004) Bedeutung des serotonergen Systems für verschiedene Aspekte der Alkoholabhängigkeit unter besonderer Berücksichtigung des Tabakkonsums. Habilitationsschrift, Medizinische Fakultät, Universität Regensburg
Wolffgramm J, Heyne A (1995) From controlled intake to loss of control: the irreversible development of drug addiction in the rat. Behav Brain Res 70: 77–94
Wolffgramm J, Galli G, Thimm F et al. (2000) Animal models of addiction: models for therapeutic strategies? J Neural Transm 107: 649–668
Young RM, Lawford BR, Nutting A et al. (2004) Advances in molecular genetics and the prevention and treatment of substance misuse: implications of association studies of the A1 allele of the D2 dopamine receptor gene. Addict Behav 29: 1275–1294
Zimmermann U, Spring K, Wittchen H-U et al. (2004a) Effects of Ethanol administration and induction of anxiety-related affective states on the acoustic startle reflex in sons of alcoholdependent fathers. Alcohol Clin Exp Res 28: 424–432
Zimmermann U, Spring K, Kunz S et al. (2004b) Effect of ethanol on hypothalamic-pituitaryadrenal system response to psychosocial stress in sons of alcohol-dependent fathers. Neuropsychopharmacol 29: 1156–1165
Zobel A, Maier W (2004) Endophänotypen — ein neues Konzept zur biologischen Charakterisierung psychischer Störungen. Nervenarzt 75: 205–214
Zuckerman M (1984) Sensation seeking: a comparative approach to human trait. Behav Brain Sci 7: 413–471
Zuckerman M (1993) P-impulsive sensation seeking and its behavioral, psychophysiological and biochemical correlates. Neuropsychobiology 28: 30–36
Zuckerman M (1994) Behavioral expressions and biosocial bases of sensation seeking. Cambridge University Press, New York
Zuckerman M, Cloninger CR (1996) Relationships between Cloninger’s, Zuckerman’s, and Eysenck’s dimensions of personality. Person Individ Diff 21: 283–285
Literatur
Bachteler D, Economidou D, Danysz W et al. (2005) The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology (im Druck)
Blizard DA, Mcclearn GE (2000) Association between ethanol and sucrose intake in the laboratory mouse: exploration via congenic strains and conditioned taste aversion. Alcohol Clin Exp Res 24: 253–258
Böning J (1992) Zur Neurobiologie und Phänomenologie eines „Suchtgedächtnisses“. Sucht 38: 105–106
Boening J (2001) Neurobiology of an addiction memory. J Neural Transm 108: 755–765
Cagetti E, Baicy KJ, Olsen RW (2004) Topiramate attenuates withdrawal signs after chronic intermittent ethanol in rats. Neuroreport 15: 207–210
Carboni E, Vacca C (2003) Conditioned place preference. A simple method for investigating reinforcing properties in laboratory animals. Methods Mol Med 79: 481–498
Chiamulera C, Epping-Jordan MP, Zocchi A et al. (2001) Reinforcing and locomotor stimulant effects of cocaine are absent in GluR5 null mutant mice. Nat Neurosci 4: 873–874
Chick J, Lehert P, Landron F et al. (2003) Does acamprosate improve reduction of drinking as well as aiding abstinence? J Psychopharmacol 17: 397–402
Ciccocioppo R, Martin-Fardon R, Weiss F (2002) Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcoholseeking behavior by drug-associated stimuli in rats. Neuropsychopharmacology 27: 391–399
Ciccocioppo R, Lin D, Martin-Fardon R et al. (2003) Reinstatement of ethanol-seeking behavior by drug cues following single versus multiple ethanol intoxication in the rat: effects of naltrexone. Psychopharmacology 168: 208–215
Coper H, Rommelspacher H, Wolffgramm J (1990) The ‘point of no return’ as a target of experimental research on drug dependence. Drug Alcohol Depend 25: 129–134
Cunningham CL, Ferree NK, Howard MA (2003) Apparatus bias and place conditioning with ethanol in mice. Psychopharmacology 170: 409–422
Ehrenreich H, Krampe H (2004) Does disulfiram have a role in alcoholism treatment today? Not to forget about disulfiram’s psychological effects. Addiction 99: 26–27
Epstein DH, Preston KL (2003) The reinstatement model and relapse prevention: a clinical perspective. Psychopharmacology 168: 31–41
Files FJ, Samson HH, Denning CE (1997) Effects of sucrose-substitution initiation on patterns of drinking by Lewis rats during continuous alcohol access. Alcohol 14: 379–387
Fiorillo CD, Tobler PN, Schultz W (2003) Discrete coding of reward probability and uncertainty by dopamine neurons. Science 299: 1898–1902
Galli G, Wolffgramm J (2004) Long-term voluntary d-amphetamine consumption and behavioral predictors for subsequent d-amphetamine addiction in rats. Drug Alcohol Depend 73: 51–60
Gaveriaux-Ruff C, Kieffer BL (2002) Opioid receptor genes inactivated in mice: the highlights. Neuropeptides 36: 62–71
Heyne A (1996a) Die selbstbestimmte Einnahme eines Opiates durch Wistarratten. Dissertation, Freie Universität Berlin (Verlag Dr. Kovac, Hamburg)
Heyne A (1996b) The development of opiate addiction in the rat. Pharmacol Biochem Behav 53: 11–25
Heyne A, Wolffgramm J (1998) The development of addiction to d-amphetamine in an animal model: same principles as for alcohol and opiate. Psychopharmacology 140: 510–518
Heyne A, May T, Goll P et al. (2000) Persisting consequences of drug intake: towards a memory of addiction. J Neural Transm 107: 613–638
Holt JD, Watson WP, Little HJ (2001) Studies on a model of long term alcohol drinking. Behav Brain Res 123: 193–200
Holter SM, Spanagel R (1999) Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats. Psychopharmacology 145: 360–369
Hölter SM, Danysz W, Spanagel R (2000a) Novel uncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonist MRZ 2/579 suppresses ethanol intake in long-term ethanol-experienced rats and generalizes to ethanol cue in drug discrimination procedure. J Pharmacol Exp Ther 292: 545–552
Hölter SM, Linthorst AC, Reul JM et al. (2000b) Withdrawal symptoms in a long-term model of voluntary alcohol drinking in Wistar rats. Pharmacol Biochem Behav 66: 143–151
Hummel M, Ansonoff MA, Pintar JE et al. (2004) Genetic and pharmacological manipulation of mu opioid receptors in mice reveals a differential effect on behavioral sensitization to cocaine. Neuroscience 125: 211–220
Johnson BA (2004) Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. CNS Drugs 18: 1105–1118
Johnson BA, Ait-Daoud N, Ma JZ et al. (2003) Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals. Alcohol Clin Exp Res 27: 1773–1779
Kenny PJ, Paterson NE, Boutrel B et al. (2003) Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine self-administration but not nicotine and cocaine-induced facilitation of brain reward function in rats. Ann NY Acad Sci 1003: 415–418
Kiyatkin EA (1995) Functional significance of mesolimbic dopamine. Neurosci Biobehav Rev 19: 573–598
Koob GF, Rocio M, Carrera A et al. (1998a) Substance dependence as a compulsive behavior. J Psychopharmacol 12: 39–48
Koob GF, Sanna PP, Bloom FE (1998b) Neuroscience of addiction. Neuron 21: 467–476
Lankford MF, Myers RD (1994) Genetics of alcoholism: simultaneous presentation of a chocolate drink diminishes alcohol preference in high drinking HAD rats. Pharmacol Biochem Behav 49: 417–425
Leri F, Flores J, Rodaros D et al. (2002) Blockade of stress-induced but not cocaine-induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the stria terminalis or the central nucleus of the amygdala. J Neurosci 22: 5713–5718
Liu X, Weiss F (2002) Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J Neurosci 22: 7856–7861
Liu X, Weiss F (2003) Stimulus conditioned to foot-shock stress reinstates alcohol-seeking behavior in an animal model of relapse. Psychopharmacology 168: 184–191
Mann K (2004) Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs 18: 485–504
May T, Juilfs F, Wolffgramm J (1998) Long-lasting effects of chronic m-opioid intake on the signal transmission via dopamine D1 receptors in the limbic forebrain of drug deprived rats. Neuropharmacology 37: 997–1006
McBride WJ, Le AD, Noronha A (2002) Central nervous system mechanisms in alcohol relapse. Alcohol Clin Exp Res 26: 280–286
McFarland K, Davidge SB, Lapish CC et al. (2004) Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. J Neurosci 24: 1551–1560
Mundle G, Dedner C, Schäfer G et al. (2001) Erste Eindrücke der klinischen Pilotstudie zur „Kausalen Therapie einer Opiatsucht“. In: Stetter F (Hrsg) Wege aus der Sucht, Bd 2. Suchtforschung für die Suchtkranken. Ergebnisse, Konsequenzen, Perspektiven. Neuland Verlag, Geesthacht, S 72–77
Myers RD, Melchior CL (1977) Alcohol drinking: abnormal intake caused by tetrahydropapaveroline in brain. Science 196: 554–556
Nestler EJ (2002) Common molecular and cellular substrates of addiction and memory. Neurobiol Learn Mem 78: 637–647
Nestler EJ, Aghajanian GK (1997) Molecular and cellular basis of addiction. Science 278:58–63
Reinhard C, Wolffgramm J (2005) Long-term voluntary consumption of MDMA and THC in rats is modified by individual and situational factors (zur Veröffentlichung eingereicht)
Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18: 247–291
Robinson TE, Berridge KC (2000) The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95[Suppl 2]:S91–117
Robinson TE, Berridge KC (2001) Incentive-sensitization and addiction. Addiction 96: 103–114
Rodd ZA, Bell RL, Sable HJ et al. (2004) Recent advances in animal models of alcohol craving and relapse. Pharmacol Biochem Behav 79:439–450
Samson HH, Sharpe AL, Denning C (1999) Initiation of ethanol self-administration in the rat using sucrose substitution in a sipper-tube procedure. Psychopharmacology 147: 274–279
Self DW, Nestler EJ (1995) Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 18: 463–495
Shaham Y, Erb S, Stewart J (2000) Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res Brain Res Rev 33:13–33
Shaham Y, Shalev U, Lu L et al. (2003) The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 168: 3–20
Sillaber I, Rammes G, Zimmermann S et al. (2002) Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors. Science 296: 931–933
Sinclair JD, Senter RJ (1967) Increased preference for ethanol in rats following alcohol deprivation. Psychonomic Sci 8: 11–12
Spanagel R (2000) Recent animal models of alcoholism. Alcohol Res Health 24: 124–131
Spanagel R (2003) Alcohol addiction research: from animal models to clinics. Best Pract Res Clin Gastroenterol 17: 507–518
Spanagel R, Holter SM (2000) Pharmacological validation of a new animal model of alcoholism. J Neural Transm 107: 669–680
Spanagel R, Sillaber I, Zieglgansberger W et al. (1998) Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress. Psychopharmacology 139: 391–401
Swift JQ, Roszkowski MT (1998) The use of opioid drugs in management of chronic orofacial pain. J Oral Maxillofac Surg 56: 1081–1085
Tessari M, Pilla M, Andreoli M et al. (2004) Antagonism at metabotropic glutamate 5 receptors inhibits nicotine-and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur J Pharmacol 499: 121–133
Tiffany ST, Conklin CA (2000) A cognitive processing model of alcohol craving and compulsive alcohol use. Addiction 95[Suppl 2]:S145–153
Tuszewski-Guerra G (2000) Antizipation einer Alkoholeinnahme: Veränderungen in Verhalten und Hormonkonzentrationen bei süchtigen und nicht-süchtigen Ratten. Dissertation, Freie Universität Berlin
Vengeliene V, Siegmund S, Singer MV et al. (2003) A comparative study on alcohol-preferring rat lines: effects of deprivation and stress phases on voluntary alcohol intake. Alcohol Clin Exp Res 27: 1048–1054
Wiesbeck GA, Weijers HG, Wodarz N et al. (2003) Gender-related differences in pharmacological relapse prevention with flupenthixol decanoate in detoxified alcoholics. Arch Women Ment Health 6: 259–262
Wolffgramm J (1995) Abhängigkeitsentwicklung im Tiermodell. Z Klin Psychol 24: 107–117
Wolffgramm J, Heyne A (1991) Social behavior, dominance and social deprivation of rats determine drug choice. Pharmacol Biochem Behav 38: 389–399
Wolffgramm J, Heyne A (1995) From controlled intake to loss of control: the irreversible development of drug addiction in the rat. Behav Brain Res 70: 77–94
Wolffgramm J, Heyne A (2002) Rückfällige Ratten als Modell für Therapieabbrüche? Sucht 48:456–459
Wolffgramm J, Galli G, Thimm F et al. (2000) Animal models of addiction: models for therapeutical strategies? J Neural Transm 107: 649–668
Wolffgramm J, Thimm F, Heyne A (2001) Rückprägung: eine Chance zur Heilung von Suchterkrankungen? In: Stetter F (Hrsg) Wege aus der Sucht, Bd 2. Suchtforschung für die Suchtkranken. Ergebnisse, Konsequenzen, Perspektiven. Neuland Verlag, Geesthacht, S 59–71
Literatur
Abi-Dargham A, Krystal JH, Anjilvel S et al. (1998) Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. Am J Psychiatry 155: 1550–1555
Akil H, Owens C, Gutstein H et al. (1998) Endogenous opioids: overview and current issues. Drug Alcohol Depend 51: 127–140
Ameri A (1999) Wie wird der Glücksgenerator im Gehirn stimuliert? Extracta Psychiatrica 12: 24–27
Atack JR (2003) Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Curr Drug Target CNS Neurol Disord 2: 213–32
Balldin JI, Berggren UC, Lindstedt G (1992) Neuroendocrine evidence for reduced dopamine receptor sensitivity in alcoholism. Am Clin Exp Res 16: 71–74
Balldin JI, Berggren UC, Lindstedt G et al. (1993) Further neuroendocrine evidence for reduced D2 dopamine receptor function in alcoholism. Drug Alcohol Depend 32: 159–162
Baumgarten HG, Grozdanovic Z (1997) Anatomy of central serotoninergic projection systems. In: Baumgarten HG, Göthert (eds) Serotoninergic neurons and 5-HT receptors in the ZNS. Springer, Berlin Heidelberg New York Tokyo, pp 41–89 (Handb Exp Pharmacol 129)
Benkert O, Hippius H (2000) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin Heidelberg New York Tokyo
Benwell MEM, Balfour DJK (1979) Effects of nicotine administration and ist withdrawal on plasma corticosterone and brain 5-hydroxindoles. Psychopharmacology 63: 7–11
Berezhnoy D, Nyfeler Y, Gonthier A et al. (2004) On the benzodiazepine binding pocket in GABAA-receptors. J Biol Chem 279: 3160–3168
Berridge KC, Robinson TE (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev 28: 309–369
Blum K, Noble EP, Sheridan PJ et al. (1990) Allelic association of human dopamine D2-receptor gene in alcoholism. JAMA 263: 2055–2060
Bond C, Laforge KS, Tian M et al. (1998) Singlenucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci 95: 9608–9613
Boot BP, Mcgregor IS, Hall W (2000) MDMA (Extasy) neurotoxicity: assessing and communicating the risks. Lancet 355: 1818–1821
Buck KJ, Metten P, Belknap JK et al. (1997) Quantitative trait loci involved in genetic predisposition to acute alcohol withdrawal in mice. J Neurosci 17: 3946–3955
Buisson B, Bertrand D (2001) Chronic exposure to nicotine upregulates the human α4β2 nicotinic acetylcholine receptor function. J Neurosci 21: 1819–1829
Carboni S, Isola R, Gessa GL et al. (1993) Ethanol prevents the glutamate release induced by N-methyl-D-aspartate in the rat striatum. Neurosci Lett 152: 133–136
Chakrabarti S, Law P-Y, Loh HH (1995) Neuroblastoma neuro2A cells stably expressing a cloned mu-opioid receptor: a specific cellular model to study acute and chronic effects of morphine. Mol Brain Res 30: 269–278
Chakrabarti S, Wang I, Tang W-J et al. (1998) Chronic morphine augments adenylyl cyclase phosphorylation: relevance to altered signaling during tolerance/dependence. Mol Pharmacol 54: 949–953
Champtiaux N, Gotti C, Cordero-Erausquin M et al. (2003) Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci 23: 7820–7829
Changeux JP, Devillers-Thiery A, Galzi JL et al. (1992) The acetylcholine receptor: a model of an allosteric membrane protein mediating intercellular communication. Ciba Found Symp 164: 66–89
Cheung HH, Gurd JW (2001) Tyrosine phosphorylation of the N-methyl_D-aspartate receptor by exogenous and postsynaptic density-associated Src-family kinases. J Neurochem 78: 524–534
Collingridge GL, Lester RA (1989) Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol Rev 41: 143–210
Copper JR, Bloom FE, Roth RH (1991) The biochemical basis of neuropharmacology, 6th edn. Oxford University Press, New York
Dahchour A, Quertemont E, de Witte P (1994) Acute ethanol increases taurine but neither glutamate nor GABA in the nucleus accumbens of male rats: a microdialysis study. Alcohol Alcoholism 29: 485–487
Dahchour A, Quertemont E, de Witte P (1996) Taurine increases in the nucleus accumbens microdialysate after acute ethanol administration to naive and chronically alcoholised rats. Brain Res 735: 9–19
Dani JA, Heinemann S (1996) Molecular and cellular aspects of nicotine abuse. Neuron 16: 905–908
Dani JA, de Biasi M (2001) Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70: 439–446
Davis KM, Wu JY (2001) Role of glutamatergic and GABAergic systems in alcoholism. J Biomed Sci 8: 7–19
de Vries TJ, Shippenberg TS (2002) Neural systems underlying opiate addiction. J Neurosci 22: 3321–3325
Devillers-Thiéry A, Galzi JL, Eiselé JL et al. (1993) Functional architecture of the nicotinic acetylcholine receptor: a prototype of ligand-gated ion channels. J Memb Biol 136: 97–112
Di Chiara G (1995) The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 38: 95–137
Di Chiara G (1997) Alcohol and dopamine. Alcohol Health Res World 21: 108–113
Elgoyhen AB, Johnson DS, Boulter J et al. (1994) α9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 79: 705–715
Elgoyhen AB, Vetter DE, Katz E et al. (2001) α10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc Natl Acad Sci USA 98: 3501–3506
Fábián G (2001) Heterotrimeric G-proteins and their role in opioid receptor function. Acta Biol Szeged 45: 13–21
Fehr C, Rademacher BL, Buck KJ (2003) Evaluation of the glutamate decarboxylase genes Gad1 and Gad2 as candidate genes for acute ethanol withdrawal severity in mice. Prog Neuropsychopharmacol Biol Psychiatry 27: 467–472
Fils-Aime ML, Eckhardt MJ, George DT et al. (1996) Early-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindolacetic acid levels than late-onset alcoholics. Arch Gen Psychiatry 53: 211–216
Flores CM, Rogers SW, Pabreza LA et al. (1991) A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is upregulated by chronic nicotine treatment. Mol Pharmacol 41: 31–37
Forth W (1996) Allgemeine und spezielle Pharmakologie und Toxikologie, 7 Aufl. Spektrum Verlag, Heidelberg
Froehlich JC (1997) Opioid peptides. Alcohol Health Res World 21: 132–136
Gardner EL, Vorel SR (1998) Cannabinoid transmission and reward-related events. Neurobiol Dis 5(6 Pt B): 502–533
Ghozland S, Matthes HW, Simonin F et al. (2002) Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 22: 1146–1154
Gintzler AR, Chakrabarti S (2000) Opioid tolerance and the emergence of new opioid receptor — coupled signaling. Mol Neurobiol 21: 21–33
Glennon RA, Dukat M, Westkaemper RB (1999) Serotonin receptors and ligands. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York
Gonzales RA, Weiss F (1998) Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanolinduced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 18: 10663–10671
Gorwood P, Martes MP, Ades J et al. (1995) Lack of association between alcohol-dependence and D3 dopamine receptor gene in three independent samples. Am J Med Genet 60: 529–531
Heinemann S, Boulter J, Deneris E et al. (1990) The brain nicotinic acetylcholine receptor gene family. Prog Brain Res 86: 195–203
Heinz A (2000) Das dopaminerge Verstärkungssystem: Funktion, Interaktion mit anderen Neurotransmittersystemen und psychopathologische Korrelate. In: Hippius H, Sass H, Sauer H (Hrsg) Monographien aus dem Gesamtgebiet der Psychiatrie. Steinkopff, Darmstadt
Heinz A, Goldman D (2000) Genotype effects on neurodegeneration and neuroadaption in monoaminergic neurotransmitter systems. Neurochem Int 37: 425–432
Heinz A, Mann K (2001) Neurobiologie der Alkoholabhängigkeit. Dtsch Ärztebl Serie: Alkoholismus 36: 2279–2285
Heinz A, Batra A (2003) Neurobiologie der Alkoholabhängigkeit. In: Brandt T, Cohen R, Helmchen H et al. (Hrsg) Psychiatrie, Neurologie, Klinische Psychologie. Grundlagen, Methoden, Ergebnisse. Kohlhammer, Stuttgart
Heinz A, Dettling M, Kuhn S et al. (1995) Blunted growth hormone response is associated with early relapse in alcohol-dependent patients. Alc Clin Exp Res 19: 62–65
Heinz A, Dufeu P, Kuhn S et al. (1996a) Psychopathological and behavioral correlates of dopaminergic sensitivity in alcohol-dependent patients. Arch Gen Psychiatry 53: 1123–1128
Heinz A, Sander T, Harms H et al. (1996b) Lack of allelic associatin of dopamine D1 and D2 (TaqA1) receptor gene polymorphism with reduced dopaminergic sensitivity in alcoholism. Alc Clin Exp Res 20: 1109–1113
Heinz A, Higley JD, Gorey JG et al. (1998) In vivo association between alcohol intoxication, aggression, and serotonin transporter availability in nonhuman primates. Am J Psychiatry 155: 1023–1028
Herz A (1997) Endogenous opioid systems and alcohol addiction. Psychopharmacology 129: 99–111
Higley JD, Suomi SJ, Linnoila M (1991) CSF monoamine metabolite concentrations vary according to age, rearing, and sex, and are influenced by the stressor of social separation in rhesus monkeys. Psychopharmacology 103: 551–556
Higley JD, Suomi SJ, Linnoila M (1996) A nonhuman primate model of type II excessive alcohol consumption. Alc Clin Exp Res 20: 629–650
Higuchi S, Muramatsu T, Matsushita S et al. (1996) No evidence of association between structural polymorphism at the dopamine D3-receptor locus and alcoholism in the Japanese. Am J Med Gen 26: 412–414
Hogg RC, Raggenbass M, Bertrand D (2003) Nicotinic acetylcholine receptors: from structure to brain function. Rev Physiol Biochem Pharmacol 147: 1–46
Hollt V (2002) A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans. Pharmacogenetics 12: 1–2
Imperato A, di Chiara G (1986) Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther 239: 219–228
Ishikawa H, Ohtsuki T, Ishiguro H et al. (1999) Association between serotonin transporter gene polymorphism and smoking among Japanese males. Cancer Epidemiol Biomarkers Prev 8: 831–833
Kaplan JR, Martin LJ, Comuzzie AG et al. (2000) Heritability of monoaminergic metabolites measured in the cerebrospinal fluid of baboons. Soc Neurosci Abstr 26: 1439
Kieffer BL (1999) Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20: 19–26
Klink R, de Kerchove D’Exaerde, Zoli M et al. (2001) Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci 21: 1452–1463
Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278: 52–58
Korpi ER (1994) Role of GABAA-receptors in the actions of alcohol and in alcoholism: recent advances. Alcohol 29: 115–129
Kotler M, Cohen H, Kremer I et al. (1999) No association between the serotonin transporter promoter region (5-HTTLPR) and the dopamine D3-receptor (BalI D3DR) polymorphisms and heroin addiction. Mol Psychiatry 4: 313–314
Kreek MJ (1996) Cocaine, dopamine and the endogenous opioid system. J Addict Dis 15: 73–96
Kruger H, Wilce PA, Shanley BC (1993) Ethanol and protein kinase C in rat brain. Neurochem Int 22: 575–581
Kumari M, Ticku MK (2000) Regulation of NMDA receptors by ethanol. Prog Drug Res 54: 152–189
Kuryatov A, Olale F, Cooper J et al. (2000a) Human α2 AchR subtypes: subunit composition, assembly, and pharmacological responses. Neuropharmacology 39: 2570–2590
Kuryatov A, Olale FA, Choi C et al. (2000b) Acetylcholine receptor extracellular domain determines sensitivity to nicotine-induced inactivation. Eur J Pharmacol 393: 11–21
LaForge KS, Yuferov V, Kreek MJ (2000) Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur J Pharm 410: 249–268
Lappalainen J, Long JC, Eggert M et al. (1998) Linkage of antisocial alcoholism to the serotonin 5-HT1B receptor gene in 2 populations. Arch Gen Psychiatry 55: 989–994
Le Foll B, Schwartz JC, Solokoff P (2000) Dopamine D3-receptor agents as potential new medication for drug addiction. Eur Psychiatry 15: 140–146
Le Novére N, Changeux J-P (1995) Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J Mol Evol 40: 155–172
Lesch KP, Bengel D, Heils A et al. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527–1531
Lindstrom J (1996) Neuronal nicotinic acetylcholine receptors. Ion Channels 4: 377–450
Lindstrom JM (2003) Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology. Ann NY Acad Sci 998: 41–52
Lingford-Huges A, Nutt D (2003) Neurobiology of addiction and implications for treatment. Br J Psychiatry 182: 97–100
Liu JG, Anand KJ (2001) Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence. Brain Res Brain Res Rev 38: 1–19
Lovinger DM (1997) Serotonin’s role in alcohol’s effects on the brain. Alcohol Health Res World 21: 114–120
Lovinger DM, White G, Weight FF (1989) Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 243: 1721–1724
Lovinger DM, Zhou Q (1994) Alcohols potentiate ion current mediated by recombinant 5-HT3RA receptors expressed in a mammalian cell line. Neuropharmacology 33: 1567–1572
Luetje CW, Patrick J (1991) Both alpha-and beta-subunits contribute to the agonist sensivity of the neuronal nicotinic acetylcholine receptor. J Neurosci 11: 837–845
Maldonado R, Rodriguez De Fonseca F (2002) Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 22: 3326–3331
Mansvelder HD, McGehee DS (2002) Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 53: 606–617
Mascia MP, Trudell JR, Harris RA (2000) Specific binding sites for alcohol and anesthetics on ligand-gated ion channels. Proc Natl Acad Sci USA 97: 9305–9310
Matsuda LA, Lolait SJ, Brownstein MJ et al. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561–564
Mayer ML, Westbrook GL (1987) The physiology of excitatory amino acids in the vertebrate central nervous system. Prog Neurobiol 28: 197–276
Mayer P, Hollt V (2001) Allelic somatic variations in the endogenous opioid system of humans. Pharmacol Ther 91: 167–177
McGehee DS, Role LW (1995) Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 57: 521–546
McKernan RM, Whiting PJ (1996) Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci 19: 139–143
Mereu G, Yoon KW, Boi V et al. (1987) Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur J Pharmacol 141: 395–399
Michaelis EK (1998) Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog Neurobiol 54: 369–415
Mihic S, Harris A (1997) GABA and the GABAA-receptor. Alcohol Health Res World 21: 127–131
Miyakawa T, Yagi T, Kitazawa H et al. (1997) Fynkinase as a determinant of ethanol sensitivity: relation to NMDA-receptor function. Science 278: 698–701
Moghaddam B, Bolinao ML (1994) Biphasic effect of ethanol on extracellular accumulation of glutamate in the hippocampus and the nucleus accumbens. Neurosci Lett 178: 99–1002
Myers RD, Veale WL (1968) Alcohol preference in the rat: reduction following depletion of brain serotonin. Science 160: 1469–1471
Naranjo CA, Knoke DM (2001) The role of selective serotonin reuptake inhibitors in reducing alcohol consumption. J Clin Psychiatry 62[Suppl 20]: 18–25
Navarro M, Carrera MR, Fratta W et al. (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21: 5344–5350
Nevo I, Hamon M (1995) Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism. Neurochem Int 26: 305–336
Nie Z, Madamba SG, Siggins GR (1994) Ethanol inhibits glutamatergic neurotransmission in nucleus accumbens neurons by multiple mechanisms. J Pharmacol Exp Ther 271: 1566–1573
Nielsen DA, Virkkunen M, Lappalainen J et al. (1998) A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch Gen Psychiatry 55: 593–602
Nille U (2000) Zur Neurobiologie des Alkoholismus. Abhängigkeiten 3: 27–31
Noble EP, Blum K, Ritchie T et al. (1991) Allelic association of the D2 receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 48: 648–654
OMIM (2004) Online mendelian inheritance in men: OPIOID RECEPTOR, MU-1; OPRM1; *600018; Genbank; www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600018
Pandey SC (1998) Neuronal signaling systems and ethanol dependence. Mol Neurobiol 17: 1–15
Pandey SC, Davis JM, Pandey GN (1995) Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates. J Psychiatry Neurosci 20: 215–225
Parsian A, Chakraverty S, Fisher L et al. (1997) No association between polymorphism in the human dopamine D3-and D4-receptors genes and alcoholism. Am J Med Genet 74: 281–285
Patkar AA, Berrettini WH, Hoehe M et al. (2001) Serotonin transporter (5-HTT) gene polymorphisms and susceptibility to cocaine dependence among African-American individuals. Addict Biol 6: 337–345
Pato CN, Macchiardi F, Pato MT et al. (1993) Review of the putative association of the D2 dopamine receptor and alcoholism: a metaanalysis. Am J Genet (Neuropsychiatr Genet) 48: 78–82
Picciotto MR, Corrigall WA (2002) Neuronal systems underlying behaviours related to nicotine addiction: neural circuits and molecular genetics. J Neurosci 22: 3338–3341
Picciotto MR, Zoli M, Rimondini R et al. (1998) Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391: 173–177
Pilla M, Perachon S, Sautel F et al. (1999) Selective inhibition of kokaine-seeking behaviour by a partial dopamine D3-receptor agonist. Nature 400: 371–375
Rivera M, Gintzler RA (1998) Differential effect of chronic morphine on mRNA encoding adenylyl cyclase isoforms: relevance to physiological sequela of tolerance/dependence. Mol Brain Res 54: 165–169
Robinson TE, Berridge KC (1993) The neural basis of drug craving: anincentiv-sensitization theory od addiction. Brain Res Brain Res Rev 18: 247–291
Roivainen R, Hundle B, Messing RO (1994) Proteinkinase C and adaption to ethanol. In: Jansson B, Jornvall H, Rydberg U et al. (eds) Toward a molecular basis of alcohol use and abuse. Birkhäuser, Basel, pp 29–38
Role LW (1992) Diversity in primary structure and function of neuronal nicotinic acetylcholine receptor channels. Curr Opin Neurobiol 2: 254–262
Rommelspacher H, Raeder C, Kaulen P et al. (1992) Adaptive changes of dopamine-D2-Receptors in rat brain following ethanol withdrawal: a quantitative autoradiographic investigation. Alcohol 9: 1–8
Rossetti ZL, Melis F, Carboni S et al. (1992) Alcohol withdrawal in rats is associated with a marked fall in extraneural dopamine. Alc Clin Exp Res 16: 529–532
Rush R, Kuryatov A, Nelson ME et al. (2002) First and second transmembrane segments of 3, 4, 2, and 4 nicotinic acetylcholine receptor subunits influence the efficacy and potency of nicotine. Mol Pharmacol 61: 1416–1422
Sander T, Harms H, Dufeu P et al. (1998) Serotonin transporter gene variants in alcohol-dependent subjects with dissocial personality disorder. Biol Psychiatry 43: 908–912
Sargent PB (1993) The diversity of neuronal nicotinic acetylcholine receptors. Annu Rev Neurosci 16: 403–443
Schmeller T, Sporer F, Sauerwein M et al. (1995) Binding of tropane alkaloids to nicotinic and muscarinic acetylcholine receptors. Pharmazie 50: 493–495
Schuckit MA, Mazzanti C, Smith TL (1999) Selective genotyping for the role of 5-HT2A, 5-HT2C, und GABAAa6 receptors and the serotonin transporter in the level of response to alcohol: a pilot study. Biol Psychiatry 45: 647–651
Schultz W, Dayan P Montague PR (1997) A neural substrate of prediction and reward. Sience 275: 1593–1599
Schumann G, Rujescu D, Kissling C et al. (2003c) Analysis of genetic variations of protein tyrosine kinase fyn and their association with alcohol dependence in two independent cohorts. Biol Psychiatry 54: 1422–1426
Schumann G, Rujescu D, Szegedi A et al. (2003a) No association of alcohol dependence with a NMDA-receptor 2B gene variant. Mol Psychiatry 8: 11–12
Schumann G, Spanagel R, Mann K (2003b) Candidate genes for alcohol dependence: animal studies. Alcohol Clin Exp Res 27: 880–888
Schwartz RD, Kellar KJ (1983) Nicotinic cholinergic receptor binding sites: in vivo regulation. Science 220: 214–216
Shimizu K, Matsubara K, Uezono T et al. (1998) Reduced dorsal hippocampal glutamate release significantly correlates with the spatial memory deficits produced by benzodiazepines and ethanol. Neuroscience 83: 701–706
Shippenberg TS, Herz A (1987) Place preference conditioning reveals the involvment of D1-dopamine receptors, in the motivational properties of μ-and κ-opioid agonists. Brain Res 436: 169–172
Sigel E (2002) Mapping of the benzodiazepine recognition site on GABA(A) receptors. Curr Top Med Chem 2: 833–839
Sim LJ, Selley DE, Dworkin SI et al. (1996) Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 16: 2684–2492
Slater SJ, Cox KJA, Lombardi JV et al. (1993) Inhibition of protein kinase C by alcohols and anaesthetics. Nature 364: 82–84
Smith AP, Lee NM (2003) Opioid receptor interactions: local and nonlocal, symmetric and asymmetric, physical and functional. Life Sci 73: 1873–1893
Spanagel R, Bienkowski P (2002) Glutamatergic mechanisms in alcohol dependence and addiction. In: Lodge D, Danysz W, Parsons FP (eds) Therapeutic potential of ionotropic glutamate receptor antagonists and modulators. Graham Publishing Co., pp 375–403
Spanagel R, Herz A, Shippenberg TS (1992) Opposing tonically active endogeneous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89: 2046–2050
Stolerman IP, Jarvis MJ (1995) The scientific case that nicotine is addictive. Psychopharmacology 117: 2–10
Tomkins DM, Tampakeras M (1999) Effects of discrete central injections of 5-HT1B agonists on ethanol self-administration. Alc Clin Exp Res 23: 20A
Tsai G, Coyle JT (1998) The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med 49: 173–184
Tsai G, Gastfried DR, Coyle T (1995) The glutamatergic basic of human alcoholism. Am J Psychiatry 153: 332–340
Türker T, Sodmann R, Goebel U et al. (1998) High ethanol tolerance in young adults is associated with the low-activity variant of the promoter of the human serotonin transporter gene. Neurosci Lett 248: 147–150
Tyndale RF (2003) Genetics of alcoholism and tobacco use in humans. Ann Med 35: 94–121
Ueno S, Wick MJ, Ye Q et al. (1999) Subunit mutations affect ethanol actions on GABA(A) receptors expressed in Xenopus oocytes. Br J Pharmacol 127: 377–82
Unterwald EM (2001) Regulation of opioid receptors by cocaine. Ann NY Acad Sci 937: 74–92
Verheul R, van den Brink W, Geerlings P (1999) A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol 34: 197–222
Voet D, Voet JG (1990) Biochemistry. Wiley and Sons, New York Chichester Brisbane Toronto Singapure
Wafford KA, Whiting PJ (1992) Ethanol potentiation of GABAA receptors requires phosphorylation of the alternatively spliced variant of the γ2 subunit. FEBS Lett 313: 113–117
Wang F, Nelson ME, Kuryatov A et al. (1998) Chronic nicotine treatment up-regulates human α3β2 but not α3β4 acetylcholine receptors stably transfected in human embryonic kidney cells. J Biol Chem 273: 28721–2873
Weed MR, Wolverton WL (1995) The reinforcing effects of dopamine D1-receptor agonists in the rhesus monkeys. J Pharmacol Exp Ther 275: 1367–1374
Whiting P, Schoepfer R, Lindstrom J et al. (1991) Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor subtype stably expressed in mouse fibroblast. Mol Pharmacol 40: 463–472
Whiting PJ, Mckernan RM, Wafford KA (1995) Structure and pharmacology of vertebrate GABAA receptor subtypes. In: Bradley RJ, Harris RA (eds) International review of neurobiology. Academic Press, San Diego
Whitten RJ, Maitra R, Reynolds JN (1996) Modulation of GABAA receptor function by alcohols: effects of subunit composition and differential effects of ethanol. Alcoholism: Clin Exp Res 20: 1313–1319
Wise RA (1988) The neurobiology of craving: implications for the understanding of addiction. J Abnorm Psychol 97: 118–132
Yan QS, Reith ME, Yan SG et al. (1998) Effect of systemic ethanol on basal and stimulated glutamate releases in the nucleus accumbens of freely moving Sprague-Dawly rats: a microdialysis study. Neurosci Lett 258: 29–32
Zubieta J, Greenwald MK, Lombardi U et al. (2000) Buprenorphine — induced changes in muopioid receptor availability in male heroindependent volunteers: a preliminary study. Neuropsychopharmacology 23: 226–334
Literatur
Abarca C, Albrecht U, Spanagel R (2002) Cocaine sensitization and reward are under the influence of circadian genes and rhythm. Proc Natl Acad Sci USA 99: 9026–9030
Agarwal DP (1997) Molecular genetic aspects of alcohol metabolism and alcoholism. Pharmacopsychiatry 30: 79–84
American Psychiatric Association (1994) Diagnostic criteria from DSM-IV. American Psychiatric Association, Washington DC
Baer JS, Sampson PD, Barr HM et al. (2003) A 21-year longitudinal analysis of the effects of prenatal alcohol exposure on young adult drinking. Arch Gen Psychiatry 60: 377–385
Begleiter H, Porjesz B (1999) What is inherited in the predisposition toward alcoholism? A proposed model. Alcohol Clin Exp Res 23: 1125–1135
Begleiter H, Porjesz B, Reich T et al. (1998) Quantitative trait loci analysis of human event-related brain potentials: P3 voltage. Electroencephalogr Clin Neurophysiol 108: 244–2450
Berrettini WH, Ferraro TN, Alexander RC et al. (1994) Quantitative trait loci mapping of three loci controlling morphine preference using inbred mouse strains. Nature Genet 7: 54–58
Bierut LJ, Diwiddie SH, Begleiter H et al. (1998) Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking: a report from the Collaborative Study on the Genetics of Alcoholism. Arch Gen Psychiatry 55: 982–988
Bleich S, Bandelow B, Javaheripour K et al. (2003) Hyperhomocysteinemia as a new risk factor for brain shrinkage in patients with alcoholism. Neurosci Lett 335: 179–182
Blum K, Noble EP, Sheridan PJ et al. (1990) Allelic association of human D2 dopamin receptor gene in alcoholism. JAMA 263: 2055–2060
Brennan PA, Grekin ER, Mortensen EL, Mednick SA (2002) Relationship of maternal smoking during pregnancy with criminal arrest and hospitalization for substance abuse in male and female adult offspring. Am J Psychiatry 159: 48–54
Buck KJ, Hood HM (1998) Genetic association of a GABA(A)-receptor gamma2 subunit variant with severity of acute physiological dependence on alcohol. Mamm Genome 9: 975–978
Bunney WE, Bunney BG, Vawter MP et al. (2003) Microarray technology: a review of new strategies to discover candidate vulnerability genes in psychiatric disorders. Am J Psychiatry 60: 657–666
Cloninger CR (1987) Neurogenetic adaptive mechanisms in alcoholism. Science 236: 410–416
Cloninger CR, Bohman M, Sigvardsson S (1981) Inheritance of alcohol abuse. Cross-fostering analysis of adopted men. Arch Gen Psychiatry 38: 861–868
Crabbe JC, Belknap JK, Buck KJ (1994) Genetic animal-models of alcohol and drug-abuse. Science 264: 1715–1723
De Witt H, Pierri J, Johanson CE (1989) Assessing individual differences in ethanol preference using a culmulative dosing procedure. Psychopharmacology 98: 113–119
Di Chiara G, Imperato A (1988) Drugs of abuse preferentially stimulate dopamine release in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274–5278
Dick DM, Nurnberger J, Edenberg HJ et al. (2002) Suggestive linkage on chromosome 1 for a quantitative alcohol-related phenotype. Alc Clin Exp Res 26: 1453–1460
Everitt BJ, Wolf ME (2002) Psychomotor stimulant addiction: a neural systems perspective. J Neurosci 22: 3312–3320
Finn PR, Pihl RO (1987) Men at high risk for alcoholism: the effect of alcohol on cardiovascular response to unavoidable shock. J Abnorm Psychol 96: 230–236
Flannery BA, Volpicelli JR, Pettinati HM (1999) Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 23: 1289–1295
Foroud T, Bucholz KK, Edenberg HJ et al. (1998) Linkage of an alcoholism-related severity phenotype to chromosome 16. Alcohol Clin Exp Res 22: 2035–2042
Franke P, Maier W (1999) Genetik des Alkoholismus. In: Soyka M (Hrsg) Klinische Alkoholismusdiagnostik. Steinkopff, Darmstadt, S 30–39
Gerrits MA, Lesscher HB, Van Ree JM (2003) Drug dependence and the endogenous opioid system. Eur Neuropsychopharmacol 13: 424–434
Gessa GL, Muntoni F, Collu M et al. (1985) Low doses of ethanol activate dopaminergic neurons of the ventral tegmental area. Brain Res 348: 201–204
Grace AA (2000) The tonic/phasic model of dopamine system regulation and its implication for understanding alcohol and psychostimulant craving. Addiction 95[Suppl 2]: S119–128
Gurling HMD, Cook CCH (1999) The genetic predisposition to alcohol dependence. Curr Opin Psychiatry 12: 269–275
Heath AC, Madden PAF (1998) Statistical methods in genetic research on smoking. Stat Methods Med Res 7: 165–186
Heath AC, Meyer J, Jardine R et al. (1991a) The inheritance of alcohol consumption patterns in a general population twin sample. II. Determinants of consumption frequency and quantity consumed. J Stud Alcohol 52: 425–433
Heath AC, Meyer J, Eaves LJ et al. (1991b) The inheritance of alcohol consumption patterns in a general population twin sample. I. Multidimensional scaling of quantity/frequency data. J Stud Alcohol 52: 345–352
Heinz A, Jones DW, Bissette G et al. (2002) Relationship between cortisol and serotonin metabolites and transporters in alcoholism. Pharmacopsychiat 35: 127–134
Helmuth L (2001) Addiction. Beyond the pleasure principle. Science 294: 983–984
Higuchi S, Matsushita S, IMazeki H et al. (1994) Aldehyde dehydrogenase genotypes in Japanese alcoholics. Lancet 343: 741–742
Jacobs, EH, Spijker S, Verhoog CW et al. (2002) Active heroin administration induces specific genomic responses in the nucleus accumbens shell. FASEB J 16: 1961–1963
Kendler KS, Jacobson KC, Prescott CA et al. (2003) Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry 160: 687–695
Koob GF (2003) Alcoholism allostasis and beyond. Alcohol Clin Exp Res 27: 232–243
Koob GF, Lemoal M (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24: 97–129
Lander ES, Schork NJ (1994) Genetic dissection of complex traits. Science 265: 2037–2048
Long JC, Knowler WC, Hanson RL et al. (1998) Evidence for genetic linkage to alcohol dependence on chromosome 4 and 11 from an autosome-wide scan in an American Indian population. Am J Med Genet 81: 216–221
Maier W (1995) Mechanismen der familiären Übertragung von Alkoholabhängigkeit und Alkoholabusus. Z Klin Psychol 24: 147–158
Meaney MJ, Diorio J, Francis D et al. (1994) Environmental regulation of the development of glucocorticoid receptor systems in the rat forebrain. The role of serotonin. Ann NY Acad Sci 746: 260–273
Merikangas KR, Stolar M, Stevens DE et al. (1998) Familial transmission of substance use disorders. Arch Gen Psychiatry 55: 973–979
Mobbs D, Greicius MD, Abdel-Azim E et al. (2003) Humor modulates the mesolimbic reward centers. Neuron 40: 1041–1048
Morgan D (2002) Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. Nat Neurosci 5: 169–174
Nestler AJ, Agjanian GK (1997) Molecular and cellular basis of addiction. Science 278: 58–63
Nestler EJ (2000) Genes and addiction. Nature Gen 26: 277–281
Nielsen DA, Virkkunen M, Lappalainen J et al. (1998) A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch Gen Psychiatry 55: 593–602
Prescott CA, Kendler KS (1999) Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins. Am J Psychiatry 156: 34–40
Reich T, Edenberg HJ, Goate A et al. (1998) Genome-wide search for genes affecting the risk for alcohol dependence. Am J Med Genet 81: 207–215
Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 18: 247–291
Schmidt LG, Harms H, Kuhn S et al. (1998) Modification of alcohol withdrawal by the A9 allele of the dopamine transporter gene. Am J Psychiatry 155: 474–478
Schuckit MA (1994) Low levels of response to alcohol as a predictor of future alcoholism. Am J Psychiatry 151: 184–189
Schuckit MA, Mazzanti C, Smith TL et al. (1999) Selective genotyping for the role of 5-HT2A, 5-HT-2C, and GABA α6 receptors and the serotonin transporter in the level of response to alcohol: a pilot study. Biol Psychiatry 45: 647–651
Schultz W (1997) Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol 7: 191–197
Self D (2003) Neurobiology: dopamine as chicken and egg. Nature 422: 573–574
Self DW, Nestler EJ (1998) Relapse to drug-seeking: neural and molecular mechanisms. Drug Alcohol Depend 58: 49–60
Spanagel R, Weiss F (1999) The dopamine hypothesis of reward: past and current status. Trends Neurosci 22: 521–527
Spanagel R, Herz A, Shippenberg TS (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89: 2046–2050
Tiffany ST (1990) A cognitive model of drug urges and drug-use behavior: role of automatic and nonautomatic processes. Psychol Rev 97: 147–168
True WR, Xian H, Scherrer JF et al. (1999) Common genetic vulnerability for nicotine and alcohol dependence in men. Arch Gen Psychiatry 56: 655–661
Ungless MA, Whistler JL, Malenka RC et al. (2001) Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 411: 583–587
Volkow ND, Swanson JM (2003) Variables that affect the clinical use and abuse of methyl-phenidate in the treatment of ADHD. Am J Psychiatry 160: 1909–1918
Weltgesundheitsorganisation (WHO) (2000) Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel (F). Klinisch-diagnostische Leitlinien, 4. Aufl. Huber, Bern
Wise R (1996) Neurobiology of addiction. Curr Opin Neurobiol 6: 243–251
Wolfgramm J, Heyne A (1995) From controlled drug intake to loss of control: the irreversible development of drug addiction in the rat. Behav Brain Res 70: 77–94
Zimmermann U, Hundt W, Spring K et al. (2003) Hypothalamic-pituitary-adrenal system adaptation to detoxification in alcohol-dependent patients is affected by family history of alcoholism. Biol Psychiatry 53: 75–84
Literatur
Abi-Dargham A, Krystal JH, Anjilvel S et al. (1998) Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. Am J Psychiatry 155: 1550–1555
Agartz I, Momenan R, Rawlings RR et al. (1999) Hippocampal volume in patients with alcohol dependence. Arch Gen Psychiatry 56: 356–363
Bendszus M, Weijers HG, Wiesbeck G et al. (2001) Sequential MR imaging and proton MR spectroscopy in patients who underwent recent detoxification for chronic alcoholism: correlation with clinical and neuropsychological data. Am J Neuroradiol 22: 1926–1932
Berridge KC, Robinson TE (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28: 309–369
Berridge KC, Robinson TE (2003) Parsing reward. Trends Neurosci 26: 507–514
Braus DF, Wrase J, Grusser S et al. (2001) Alcohol-associated stimuli activate the ventral striatum in abstinent alcoholics. J Neural Transm 108: 887–894
Breiter HC, Gollub RL, Weisskoff RM et al. (1997) Acute effects of cocaine on human brain activity and emotion. Neuron 19: 591–611
Breiter hc rauch sl kwong kk et al. 1996 Functional Magnetic Resonance Imaging of Symptom Provocation in Obsessive-Compulsive Disorder. Arch gen Psychiatry 53 595–606
Buchert R, Thomasius R, Nebeling B et al. (2003) Long-term effects of “ecstasy” use on serotonin transporters of the brain investigated by PET. J Nucl Med 44: 375–38
Budney AJ, Hughes JR, Moore BA et al. (2001) Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry 58: 917–924
Büttner A, Mall G, Penning R et al. (2000) The neuropathology of heroin abuse. Forensic Sci Int 113: 435–442
Chan GC, Hinds TR, Impey S et al. (1998) Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J Neurosci 18: 5322–5332
Chang L, Ernst T, Grob CS et al. (1999) Cerebral (1)H MRS alterations in recreational 3,4-methylendioxymethamphetamine (MDMA, ecstasy) users. J Magn Reson Imaging 10: 521–526
Chang L, Grob CS, Ernst T et al. (2000) Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a coregistered SPECT and MRI study. Psychiatry Res 98: 15–28
Childress AR, Mozley PD, Mcelgin W et al. (1999) Limbic activation during cue-induced cocaine craving. Am J Psychiatry 56: 11–18
Christensen JD, Kaufman MJ, Levin JM et al. (1996) Abnormal cerebral metabolism in polydrug abusers during early withdrawal: a 31P MR spectroscopy study. Magn Reson Med 35: 658–663
Dagher A, Bleicher C, Aston JA et al. (2001) Reduces dopamine D1 receptor binding in the ventral striatum of cigarette smokers. Synapse 42: 48–53
Diana M, Muntoni AL, Pistis M et al. (1999) Lasting reduction in mesolimbic dopamine neuronal activity after morphine withdrawal. Eur J Neurosci 11: 1037–1041
Doudet D, Hommer D, Higley JD et al. (1995) Cerebral glucose metabolism, CSF 5-HIAA levels, and aggressive behavior in rhesus monkeys. Am J Psychiatry 152: 1782–1787
Drevets WC, Gautier C, Price JC et al. (2001) Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 49: 81–96
Ernst M, Matochik JA, Heishman SJ et al. (2001) Effect of nicotine on brain activation during performance of a working memory task. Proc Natl Acad Sci USA 98: 4728–4733
Ferrucci M, Gesi M, Lenzi P et al. (2002) Noradrenergic loss enhances MDMA toxicity and induces ubiquitin-positive striatal whorls. Neurol Sci [Suppl 2]: 75–76
Fischer C, Hatzidimitriou G, Wlos J et al. (1995) Reorganization of ascending 5-hat axon projections in animals previously exposed to the recreational drug 3,4-methylendioxymethamphetamine (MDMA, Ecstasy). J Neurosci 15: 5476–5485
Fletcher JM, Page JB, Francis DJ et al. (1996) Cognitive correlates of long-term cannabis use in Costa Rican men. Arch Gen Psychiatry 53: 1051–1057
Fowler JS, Wang G-J, Volkow ND (1996) Inhibition of monoamine oxidase B in brains of smokers. Nature 379: 733–736
Fowler JS, Wang GJ, Volkow ND et al. (1999) Smoking a single cigarette does not produce a measurable reduction in brain MAO B in non smokers. Nicotine Tobacco Res 1: 325–329
Franklin TR, Acton PD, Maldjian JA et al. (2002) Decreased gray matter concentration in the insular, orbitofrontal, cingulate, and temporal cortices of cocaine patients. Biol Psychiatry 51: 134–142
Galynker II, Watras-Ganz S, Miner C et al. (2000) Cerebral metabolism in opiate-dependent subjects: effects of methadone maintenance. Mt Sinai J Med 67: 381–387
Garavan H, Pankiewicz J, Bloom A et al. (2000) Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. Am J Psychiatry 157: 1789–1798
Garavan H, Ross TJ, Stein EA (1999) Right hemispheric dominance of inhibitory control: an event-related functional MRI study. Proc Natl Acad Sci USA 96: 8301–8306
George DT, Lindquist T, Rawlings RR et al. (1992) Pharmacologic maintenance of abstinence in patients with alcoholism: no efficacy of 5-hydroxytryptophan or levodopa. Clin Pharmacol Ther 52: 553–560
Ghatan PH, Ingvar M, Eriksson L et al. (1998) Cerebral effects of nicotine during cognition in smokers and non-smokers. Psychopharmacology (Berl) 136: 179–189
Giove F, Mangia S, Bianciardi M et al. (2003) The physiology and metabolism of neuronal activation: in vivo studies by NMR and other methods. Magn Reson Imaging 1: 283–293
Goldstein RZ, Volkow ND (2002) Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159: 1642–1652
Grant S, London ED, Newlin DB et al. (1996) Activation of memory circuits during cue-elicited cocaine craving. Proc Natl Acad Sci USA 93: 12040–12045
Grusser SM, Heinz A, Flor H (2000) Standardized stimuli to assess drug craving and drug memory in addicts. J Neural Transm 107: 715–720
Hatzidimitriou G, Mccann DU, Ricuarte GA (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with 3,4-methylendioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19: 5096–5107
Heath RG, Fitzjarrell AT, Fontana CJ et al. (1980) Cannabis sativa: effects on brain function and ultrastructure in rhesus monkeys. Biol Psychiatry 15: 657–690
Heinz A (2002) Dopaminergic dysfunction in alcoholism and schizophrenia — psychopathological and behavioral correlates. Eur Psychiatry 17: 9–16
Heinz A, Batra A (2003) Neurobiologie der Alkohol und Nikotinabhängigkeit. In: Brandt T, Cohen R, Helmchen H, Schmidt L (Hrsg) Psychiatrie, Neurologie, Klinische Psychologie. Kohlhammer, Stuttgart
Heinz A, Goldman D (2000) Genotype effects on neurodegeneration and neuroadaptation in monoaminergic neurotransmitter systems. Neurochem Int 37: 425–432
Heinz A, Jones DW (2000) Serotonin transporters in ecstasy users. Br J Psychiatry 176: 193
Heinz A, Dufeu P, Kuhn S et al. (1996) Psychopathological and behavioral correlates of dopaminergic sensitivity in alcohol-dependent patients. Arch Gen Psychiatry 53: 1123–1128
Heinz A, Ragan P, Jones DW et al. (1998) Reduced central serotonin transporters in alcoholism. Am J Psychiatry 155: 1544–1549
Heinz A, Mann K, Weinberger DR et al. (2001) Serotonergic dysfunction, negative mood states, and response to alcohol. Alcohol Clin Exp Res 25: 487–495
Heinz A, Smolka MN, Mann K (2003a) Brain imaging in opiate addiction. In: Kuntze MF, Müllerspahn F, Ladewig D et al. (eds) Basic and clinical science of opioid addiction. Karger, Basel Freiburg Paris, S 46–54
Heinz A, Jones DW, Gorey JG et al. (2003b) Serotonin transporter availability correlates with alcohol intake in non-human primates. Mol Psychiatry 8: 231–234
Herman BH, O’Brien CP (1997) Clinical medications development for opiate addiction: focus on nonopioids and opioid antagonists for the amelioration of opiate withdrawal symptoms and relapse prevention. Semin Neurosci 9:158–172
Higley JD, Suomi SJ, Linnoila M (1996) A nonhuman primate model of type II alcoholism, part 2. Diminished social competence and excessive aggression correlates with low cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations. Alcohol Clin Exp Res 20: 643–650
Hollister LE (1998) Health aspects of cannabis: revisited. Int J Neuropsychopharmacol 1: 71–80
Hommer D, Momenan R, Rawlings R et al. (1996) Decreased corpus callosum size among alcoholic women. Arch Neurol 53: 359–363
Howell LL, Hoffmann JM, Votaw JR et al. (2003) Cocaine-induced brain activation determined by positron emission tomography neuroimaging in conscious rhesus monkeys. Psychopharmacology 159: 154–160
Hurt RD, Sachs D, Glover ED et al. (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337: 1195–1202
Iversen L (2003) Cannabis and the brain. Brain 126: 1252–1270
Jacobsen LK, Giedd JN, Gottschalk C et al. (2001) Quantitative morphology of the caudate and putamen in patients with cocaine dependence. Am J Psychiatry 158: 486–489
Jorenby DE, Leischow SJ, Nides MA et al. (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340: 685–689
Kaufman MJ, Pollack MH, Villafuerte RA et al. (1999) Cerebral phosphorus metabolite abnormalities in opiate-dependent polydrug abusers in methadone maintenance. Psychiatry Res 90: 143–152
Koob GF, le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278: 52–58
Krystal JH, Woods SW, Kosten TR et al. (1995) Opiate dependence and withdrawal: preliminary assesment using single photon emission computerized tomography (SPECT). Am J Drug Alcohol Abuse 21: 47–63
Landfield PW, Cadwallader LB, Vinsant S (1988) Quantitative changes in hippocampal structure following long-term exposure to delta 9-tetrahydrocannabinol: possible mediation by glucocorticoid systems. Brain Res 443: 47–62
Laruelle M, Abi-Dargham A, van Dyck CH et al. (1995) SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36: 1182–1190
Laruelle M, D’Souza CD, Baldwin RM et al. (1997) Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17: 162–174
Lim KO, Choi SJ, Pomara N, Wolkin A et al. (2002) Reduced frontal white matter integrity in cocaine dependence: a controlled diffusion tensor imaging study. Biol Psychiatry 51: 890–895
London ED, Ernst M, Grant S et al. (2000) Orbitofrontal cortex and human drug abuse: functional imaging. Cereb Cortex 10: 334–342
Maas LC, Lukas SE, Kaufman MJ et al. (1998) Functional magnetic resonance imaging of human brain activation during cue-induced cocaine craving. Am J Psychiatry 155: 124–126
Malison RT, Mccance E, Carpenter LL et al. (1998) [123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts. Psychopharmacology (Berl) 137: 321–235
Mann K, Agartz I, Harper C et al. (2001) Neuroimaging in alcoholism: ethanol and brain damage. Alcohol Clin Exp Res 25[5 Suppl ISBRA]:104S–109S
Myrick H, Anton RF, Li X et al. (2004) Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving. Neuropsychopharmacology 29: 393–402
Noble F, Cox BM (1996) Differential desensitization of m-and δ-opioid receptors in selected neural pathways following chronic morphine treatment. Br J Pharmacol 117: 161–169
O’Brien CP (2003) Research advances in the understanding and treatment of addiction. Am J Addict 12[Suppl 2]: S36–47
Panikkar GP (1999) Cocaine addiction: neurobiology and related current research in pharmacotherapy. Subst Abuse 20: 149–166
Papp M, Klimek V, Willner P (1994) Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology 115: 441–446
Paulus MP, Hozack NE, Zauscher BE et al. (2002) Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology 26: 53–63
Pfefferbaum A, Sullivan EV, Mathalon DH et al. (1995) Longitudinal changes in magnetic resonance imaging brain volumes in abstinent and relapsed alcoholics. Alcohol Clin Exp Res 19: 1177–1191
Porrino LJ, Lyons D (2000) Orbital and medial prefrontal cortex and psychostimulant abuse: studies in animal models. Cereb Cortex 10:326–333
Rauch SL, Jenike MA, Alpert NM et al. (1994) Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 51: 62–70
Ricaurte GA, Yuan J, Hatzidimitriou G et al. (2003) Retraction. Science 301: 1479
Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18: 247–291
Robinson TE, Berridge KC (2003) Addiction. Annu Rev Psychol 54: 25–53
Robinson TE, Gorny G, Mitton E et al. (2001) Cocaine self-administration alters the morphology of dendrites and dendritic spines in the nucleus accumbens and neocortex. Synapse 39: 257–266
Rose RJ, Viken RJ, Dunlap JE et al. (1994) Individual differences in subjective response to alcohol challenge: data from studies of twins. Alc Clin Exp Res 18: 453
Royall DR, Lauterbach EC, Cummings JL et al. (2002) Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 14:377–405
Salmeron BJ, Stein EA (2002) Pharmacological applications of magnetic resonance imaging. Psychopharmacol Bull 36: 102–129
Salmeron BJ, Risinger RC, Ross TJ et al. (2001) Neural correlates of high and craving during human cocaine self-administration. NIDA Monograph 182
Salokangas RK, Vilkman H, Ilonen T et al. (2000) High levels of dopamine activity in the basal ganglia of cigarette smokers. Am J Psychiatry 157: 632–634
Schlaepfer TE, Strain EC, Greenberg BD et al. (1998) Site of opioid action in the human brain: mu and kappa agonists’ subjective and cerebral blood flow effects. Am J Psychiatry 155: 470–473
Schneider F, Habel U, Wagner M et al. (2001) Subcortical correlates of craving in recently abstinent alcoholic patients. Am J Psychiatry 158: 1075–1083
Schuckit MA, Smith TL (1996) An 8-year followup of 450 sons of alcoholic and control subjects. Arch Gen Psychiatry 53: 202–210
Schultz W, Dayan P, Montague PR (1997) A neural substrate of prediction and reward. Science 275: 1593–1599
Sekine Y, Iyo M, Ouchi Y et al. (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158: 1206–1214
Sora I, Hall FS, Andrews AM et al. (2001) Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci USA 98: 5300–5305
Staley JK, Krishnan-Sarin S et al. (2001) Sex differences in [123I]β-CIT SPECT measures of dopamine and serotonine transporter availability in healthy smokers and non smokers. Synapse 41: 275–284
Stolerman IP, Mirza NR, Shoaib M (1995) Nicotine psychopharmacology: addiction, cognition and neuroadaptation. Med Res Rev 15: 47–72
Sullivan EV, Lane B, Deshmukh A et al. (1999) In vivo mammillary body volume deficits in amnesic and nonamnesic alcoholics. Alcohol Clin Exp Res 23: 1629–1636
Sullivan EV, Marsh L, Mathalon DH et al. (1996) Relationship between alcohol withdrawal seizures and temporal lobe white matter volume deficits. Alcohol Clin Exp Res 20: 348–354
Thanos PK, Volkow ND, Freimuth P et al. (2001) Overexpression of dopamine D2 receptors reduces alcohol self-administration. J Neurochem 78: 1094–1103
Thomasius R, Petersen K, Buchert R et al. (2003) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl) 167: 85–96
Tiihonen J, Vilkman H, Rasanen P et al. (1998) Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography. Mol Psychiatry 3: 156–161
Tsai G, Gastfriend DR, Coyle JT (1995) The glutamatergic basis of human alcoholism. Am J Psychiatry 152: 332–340
VAN Dyck CH, Rosen MI, Thomas HM et al. (1994) SPECT regional cerebral blood flow alterations in naltrexone precipitated withdrawal from buprenorphine. Psychiatry Res 55: 181–191
Volkow ND, Chang L, Wang GJ et al. (2001) Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158: 2015–2021
Volkow ND, Fowler JS, Wang G (2003) The addicted human brain: insights from imaging studies. J Clin Invest 111: 1444–1451
Volkow ND, Fowler JS, Wang GJ et al. (1993) Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14: 169–177
Volkow ND, Wang GJ, Fischman MW et al. (1997a) Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386: 827–830
Volkow ND, Wang GJ, Fowler JS et al. (1994) Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 16: 255–262
Volkow ND, Wang GJ, Fowler JS et al. (1996) Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 20: 1594–1598
Volkow ND, Wang GJ, Fowler JS et al. (1997b) Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386: 830–833
Volkow ND, Wang GJ, Fowler JS et al. (1999a) Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 156: 1440–1443
Volkow ND, Wang GJ, Fowler JS et al. (1999b) Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 291: 409–415
Volpicelli JR, Watson NT, King AC et al. (1995) Effect of naltrexone on alcohol “high” in alcoholics. Am J Psychiatry 152: 613–615
Wang GJ, Volkow ND, Fowler JS et al. (1997) Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 16: 174–182
Weber W, Henkes H, Moller P et al. (1998) Toxic spongiform leucoencephalopathy after inhaling heroin vapour. Eur Radiol 8: 749–755
Weinstein A, Feldtkeller B, Malizia A et al. (1998) Integrating the cognitive and physiological aspects of craving. J Psychopharmacol 12: 31–38
Wexler BE, Gottschalk CH, Fulbright RK et al. (2001) Functional magnetic resonance imaging of cocaine craving. Am J Psychiatry 158:86–95
White NM (1996) Addictive drugs as reinforcers multiple partial actions on memory systems. Addiction 91: 921–949
Wrase J, Grusser SM, Klein S et al. (2002) Development of alcohol-associated cues and cueinduced brain activation in alcoholics. Eur Psychiatry 17: 287–291
Literatur
Adams RD, Victor M (eds) (1993) Principles of neurology, 5th edn. pp 66–88
Addolorato G, Castelli E, Stefanini GF et al. (1996) An open multicentre study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. Alcohol Alcoholism 31: 341–345
Addolorato G, Caputo F, Stefanini GF et al. (1997) Gamma-hydroxybutyric acid in the treatment of alcohol dependence: possible craving development for the drug. Addiction 92: 1035–1036
Addolorato G, Cibin M, Caprista E et al. (1998) Maintaining abstinence from alcohol with gamma-hydroxybutyric acid. Lancet 351: 38
Babor TF, Dolinsky Z, Meyer RE et al. (1992A) Types of alcoholics: concurrent and predictive validity of some common classification schemes. Br J Addict 87: 1415–1431
Babor TF, Hofmann M, Del Boca FK et al. (1992b) Types of alcoholics. 1. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 49: 599–608
Ballenger J, Goodwin F, Major L et al. (1979) Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry 36: 224–227
Banki CM (1981) Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence. J Neural Transm 59: 89–101
Barz J, Freudenstein P, Bonte W et al. (1988) Besonderheiten des Methanolstoffwechsels bei chronischen Alkoholikern. Wiener Z Suchtforsch 11/4: 25–28
Baumann P (Hrsg) (1994) Biologische Psychiatrie der Gegenwart. Springer, Wien New York, S 636–640
Berner P, Lesch OM, Walter H (1986) Alcohol and depression. Psychopathology 19/2: 177–183
Besson J, Aeby F, Kasas A et al. (1998) Combined efficacy of acamprosate and disulfirame in the treatment of alcoholism: a controlled study. Alcoholism: Clin Exp Res 22/3: 573–579
Bleich S, Bayerlein K, Reulbach U et al. (2004) Homocysteine levels in patients classified to Lesch’s typology. Alcohol Alcoholism (in press)
Carroll KM, Nich C, Ball SA et al. (2000) Oneyear follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction 95/9: 1335–1349
Chick J (1995) Acamprosate as an aid in the treatment of alcoholism. Alcohol Alcoholism 30: 785–787
Chick J, Howlett H, Morgan MY et al. (2000a) United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcoholism 35/2: 176–187
Chick J, Anton R, Checinski K et al. (2000b) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcoholism 35: 587–593
Cloninger CR, Bohman M, Sigvardsson S (1981) Inheritance of alcohol abuse: cross-fostering analysis of adopted men. Arch Gen Psychiatry 38: 861–868
Collins DM, Myers RD (1987) Buspirone attenuates volitional alcohol intake in the chronically drinking monkeys. Alcohol Alcoholism 4: 49–56
Cornelius JR, Salloum IM, Cornelius MD et al. (1995) Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. Psychopharmacol Bull 31: 297–303
Cornelius JR, Salloum IM, Ehler JG et al. (1997) Fluoxetine in depressed alcoholics: a doubleblind, placebo-controlled trial. Arch Gen Psychiatry 54: 700–705
Cornelius JR, Salloum IM, Thase ME et al. (1998) Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacol Bull 34/1: 117–121
De Witte PH, Pinto E, Ansseau M et al. (2003) Alcohol and withdrawal: from animal research to clinical issues. Neurosci Biobehav Rev 27: 189–197
Dvorak A, Ramskogler K, Hertling I et al. (2003) Alcohol dependence and depressive syndromes. Int Clin Psychopharmacol 18/1: 47–53
Eison AS, Temple DL (1986) Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am J Med 80(3B): 1–9
Engel JA, Fahlke C, Hard E et al. (1992) Serotonergic and dopaminergic involvment in ethanol intake. Clin Neuropharmacol 15[Suppl 1]: 64A–65A
Fuller RK, Branchey L, Brightwell DR et al. (1986) Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. J Am Med Assoc 256: 1449–1455
Gallimberti L, Gentile N, Cibin M et al. (1989) Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet 334/8666: 787–789
Gallimberti L, Ferri M, Ferrara SD et al. (1992) Gammahydroxybutyric acid in the treatment of alcohol dependance: a double blind study. Alcoholism: Clin Exp Res 16: 673–676
Grünberger J, Lesch OM, Linzmayer L (1988) Bestimmung von vier Alkoholikertypen mit Hilfe der statischen und lichtevozierten dynamischen Pupillometrie. Wiener Z Suchtforsch 11/4: 29–34
Guardia J, Catafau A, Batlle F et al. (2000) Striatal dopaminergic D2 receptor density measured by (123I) Iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients. Am J Psychiatry 157: 127–129
Heimann H, Mayer K, Schied HW (Hrsg) (1989) Psychiatrische und neurologische Aspekte des Alkoholismus heute. Fischer, Stuttgart, S 267–284
Heinz A (1999) Serotonerge Dysfunktion als Folge sozialer Isolation. Bedeutung für die Entstehung von Aggression und Alkoholabhängigkeit. Nervenarzt 70: 780–789
Heinz A, Dettling M, Kuhn S et al. (1995a) Blunted growth hormone response is associated with early relapse in alcohol-dependent patients. Alcoholism: Clin Exp Res 19: 62–65
Heinz A, Lichtenberg-Kraag B, Sällström-Baum S et al. (1995b) Evidence for prolonged recovery of dopaminergic transmission after detoxification in alcoholics with poor treatment outcome. J Neural Transm (Gen Sect) 102: 149–157
Hertling I, Ramskogler K, Riegler A et al. (2001a) Entzugsbehandlung von alkoholabhängigen Patienten. Wiener Z Suchtforsch 24/1: 41–46
Hertling I, Ramskogler K, Riegler A et al. (2001b) Craving for alcohol and prevention of relapse. Wien Klin Wochenschr 113/19: 717–726
Hester RK, Miller WR (eds) (2003) Handbook of alcoholism treatment approaches. Effective alternatives, 3rd edn.
Janiri L, Gobbi G, Mannelli P et al. (1996) Effects of fluoxetine at antidepressant doses on shortterm outcome of detoxified alcoholics. Int Clin Psychopharmacol 11: 109–117
Johnson BA (2000) Serotonergic agents and alcoholism treatment: rebirth of the subtype concept — a hypothesis. Alcoholism: Clin Exp Res 24: 1597–1601
Johnson BA, Ait-Daoud N (1999) Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 149: 327–344
Johnson BA, Roache JD, Javors MA et al. (2000) Odansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomised controlled trial. J Am Med Assoc 284: 963–971
Johnson BA, Ruiz P, Galanter M (eds) (2003) Handbook of clinical alcoholism treatment. Lippincot, Williams & Wilkins, Baltimore
Kabel DI, Petty F (1996) A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcoholism: Clin Exp Res 20: 780–784
Kiefer F, Barocka A (1999) Secondary depression in weaned alcoholics: implications of Lesch’s typology of chronic alcoholism. Alcohol Alcoholism 34/6: 916–917
Kiefer F, Jahn H, Tarnaska T et al. (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60: 92–99
Kiefer F, Helwig H, Tarnaske T et al. (2005) Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res 11(2): 83–91
Knapp DJ, Pohorecky LA (1992) Zacopride, a 5-HT3-receptor antagonist, reduces voluntary ethanol consumption in rats. Pharmacol Biochem Behav 41: 847–850
Koob G, Roberts A (1999) Brain reward circuits in alcoholism. CNS Spectrums 4: 23–37
Koob G, Weiss F (1992) Neuropharmacology of cocaine and ethanol dependence. Rec Dev Alcoholism 10: 201–233
Kranzler HR, Burleson JA, Delboca FK et al. (1994) Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry 51: 720–731
Kranzler HR, Burleson JA, Korner P et al. (1995) Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 152: 391–397
Kranzler HR, Burleson JA, Brown J et al. (1996) Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcoholism: Clin Exp Res 20: 1534–1541
Krejcar J, Kirchweger S, Kepplinger B (2003) Abhängigkeit als menschliches Phänomen. Edition Selva, Amstetten Linz
Krystal JH, Cramer JA, Krol WF et al. (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345/24: 1734–1739
Lee MA, Meltzer HY (1991) Neuroendocrine responses to serotonergic agents in alcoholics. Biol Psychiatry 30: 1017–1030
Lee AD, Sellers EM (1994) Interaction between opiate and 5-HT3 receptor antagonists in the regulation of alcohol intake. Alcohol Alcoholism [Suppl 2]: 545–549
Leitner A, Gierth L, Lentner S et al. (1994) Untergruppen Alkoholkranker. Gibt es biologische Marker? Harman-und Norharman-Befunde. In: Baumann P (Hrsg) Biologische Psychiatrie der Gegenwart. Springer, Wien New York, S 636–640
Lesch OM (1985) Chronischer Alkoholismus — Typen und ihr Verlauf. Eine Langzeitstudie. G Thieme, Stuttgart New York
Lesch OM, Walter H (1996) Subtypes of alcoholism and their role in therapy. Alcohol Alcoholism 31[Suppl 1]: 63–67
Lesch OM, Lesch E, Dietzel M et al. (1986) Chronischer Alkoholismus — Folgekrankheiten — Todesursachen. Wien Med Wochenschr 19: 505–515
Lesch OM, Dietzel M, Musalek M et al. (1988a) The course of alcoholism. Long term prognosis in different types. Forensic Sci Int 36: 121–138
Lesch OM, Walter H, Mader R et al. (1988b) Chronic alcoholism in relation to attempted or effected suicide — a long-term-study. Psychiatr Psychobiol 3: 181–188
Lesch OM, Kefer J, Lentner S et al. (1990) Diagnosis of chronic alcoholism — classificatory problems. Psychopathology 23: 88–96
Lesch OM, Riegler A, Gutierrez K et al. (2001) The European Acamprosate Trials: conclusions for research and therapy. J Biomed Sci 8: 89–95
Lindner H (2002) Heterogenität des Rauchverhaltens und Verlangens nach Nikotin bei alkoholabhängigen Patienten in der qualifizierten stationären Therapie — Klassifikatorische Konzepte. Dissertation, Medizinische Hochschule Hannover
Littleton J, Zieglgänsberger W (2003) Pharmacological mechanisms of naltrexone and acamprosate the prevention of relapse in alcohol dependence. Am J Addict 12: 3–11
Malcolm R, Anton RF, Randall DL et al. (1992) A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcoholism: Clin Exp Res 16: 1007–1013
Mason BJ, Kocsis JH, Ritvo EC et al. (1996) A double-blind, placebo-controlled trials of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. J Am Med Assoc 275: 761–767
Mason BJ, Ownby RL (2000) Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectrums 5: 58–69
McGrath PJ, Nunes EV, Stewart JW et al. (1996) Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry 53: 232–240
McGrath P (1998) Fluoxetine for the treatment of alcoholism and depression. In: Litten R (Chair) Does 5-HT pharmacotherapy have a role in alcohol treatment? Symposium, Annual Meeting of Research Society on Alcoholism, Hilton Head, SC
Miller WR, Meyers RJ, Tonigan JS et al. (2001) Community reinforcement and traditional approaches: findings of a controlled trial. In: Meyers RJ, Miller WR (eds) A community reinforcement approach to addiction treatment. Cambridge University Press, Cambridge, pp 79–103
Moak DH, Voronin KE, Latham PK et al. (2001) A double-blind placebo-controlled treatment study of sertraline in depressed alcoholics: preliminary analysis. Alcoholism: Clin Exp Res 25: 94A
Möller HJ (1993) Therapie psychiatrischer Erkrankungen. Enke, Stuttgart, S 634–645
Musshoff F, Daldrup T, Bonte W et al. (1995) Ethanolunabhängige Methanolelimination bei chronischen Alkoholikern. Blutalkohol 32: 317–336
Naranjo CA, Poulos CX, Lanctot KL et al. (1995) Ritanserin, a central 5-HT2 antagonists, in heavy social drinkers: desire to drink, alcohol intake and related effects. Addiction 90: 893–905
Naranjo CA, Knoke DM (2001) The role of selective serotonin reuptake inhibitors in reducing alcohol consumption. J Clin Psychiatry 62: 18–25
Nimmerrichter A, Walter H, Gutierrez-Lobos KE et al. (2002) Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcoholism 37: 67–73
Palmer NT (ed) (1991) Alcoholism: a molecular perspective. Plenum Press, New York, pp 421–444 (Nato Asci Series A: Life Sciences 206)
Peter K (Hrsg) (2002) Fortschritte in Psychiatrie und Psychotherapie. Interdisziplinäre und integrative Aspekte. Springer, Berlin Heidelberg New York Tokyo, S 83–96
Pettinatti HM (2001) The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. J Clin Psychiatry 62: 26–31
Pettinatti HM, Oslin D, Decker K (2000a) Role of serotonin and serotonin-selective pharmacotherapy in alcohol dependence. CNS Spectrums 5(2): 33–46
Pettinatti HM, Rukstalis MR, Luck GJ et al. (2000b) Gender and psychiatric comorbidity: impact on clinical presentation of alcohol dependence. Am J Addict 9: 242–252
Pettinatti HM, Volpicelli JR, Kranzler HR et al. (2000c) Sertraline treatment for alcohol dependence: interactive effects of medication and subtype. Alcoholism: Clin Exp Res 24: 1041–1049
Pettinatti HM, Volpicelli JR, Luck G et al. (2001) Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 21: 143–153
Platz WE (2004) § 29 Die Begutachtung der strafrechtlichen Verantwortung. In: Brüssow R, Gatzweiler N, Krekeler W et al. (Hrsg) Strafverteidigung in der Praxis. Deutscher Anwaltverlag, S 2312–2314 und 2334
Powell BJ, Campbell JL, Landon JF et al. (1995) A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics sub-typed by comorbid psychiatric disorders. Alcoholism: Clin Exp Res 19: 462–468
Privette TH, Hornsby RI, Myers RD (1988) Buspirone alters alcohol drinking induced in rats by tetrahydropapaveroline injected into brain monoaminergic pathways. Alcohol 5: 147–152
Ramskogler K, Walter H, Hertling I et al. (2001) Subgroups of alcohol dependence and their specific therapeutic management: a review and introduction to the Lesch-typology. Ejournal, International Society of Addiction Medicine — International Addiction
Roberts AJ, Mc Arthur RA, Hull EE et al. (1998) Effects of amperozide, 8-OH-DPAT, and FG5974 on operant responding for ethanol. Psychopharmacology 137: 25–32
Roy A (1998) Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry 44: 633–637
Roy A, Virkkunen M, Linnoila M (1990) Serotonin in suicide, violence, and alcoholism. In: Coccaro EF, Murphy DL (eds) Serotonin in major psychiatric disorders. American Psychiatric Press, Washington DC, pp 187–208
Sass H, Soyka M, Mann K et al. (1996) Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53: 673–680
Schuckit MA (1985) The clinical implications of primary diagnostic groups among alcoholics. Arch Gen Psychiatry 42: 1043–1049
Schwoon DR, Krausz M (1990) Suchtkranke — die ungeliebten Kinder der Psychiatrie. Enke, Stuttgart, S 81–91
Sinclair JD (2001) Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcoholism 36: 2–10
Soyka M (1999) Alkoholabhängigkeit — Grundlagen und Therapie. Springer, Berlin Heidelberg New York Tokyo
Sperling W, Frank H, Lesch OM et al. (1999) Untergruppen Alkoholabhängiger und ihre primäre Vulnerabilität — eine Untersuchung zweier Typologien (Cloninger, Lesch). Wiener Z Suchtforsch 22/4: 21–26
Sperling W, Frank H, Martus P et al. (2000) The concept of abnormal hemispheric organization in addiction research. Alcohol Alcoholism 35: 394–399
Sprung R, Bonte W, Lesch OM (1988) Methanol — ein bisher verkannter Bestandteil aller alkoholischen Getränke. Eine neue biochemische Annährung an das Problem des chronischen Alkoholismus. Wien Klin Wochenschr 9: 282–288
Svensson L, Fahlke C, Hard E et al. (1993) Involvement of the serotonergic system in ethanol intake in the rat. Alcohol 10: 219–224
Tiihonen J, Ryynänen OP, Kauhanen J et al. (1996) Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. Pharmacopsychiatry 29: 27–29
Tollefson GD, Montague-Clouse J, Tollefson SL (1992) Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol 12: 19–26
Volpicelli JR, Alterman AL, Hayashida M et al. (1992) Naltrexone in the treatment of alcohol dependance. Arch Gen Psychiatry 49: 876–880
Volpicelli JR (1995) Naltrexone in alcohol dependence. Lancet 346: 456
Walter H, Ramskogler K, Semler B et al. (2001) Dopamine and alcohol relapse: D1 and D2 antagonists increase relapse rates in animal studies and in clinical trials. J Biomed Sci 8: 83–88
Weller MPI, van Kammen DP (1996) Drugs of abuse. In: Rommelspacher H, Schuckit M (eds) Baillière’s clinical psychiatry, 2, 3. Baillière Tindall, London Philadelphia Sydney Tokio Toronto, pp 421–444
Wiesbeck GA, Boening J, Weijers HG et al. (2001) Flupentixol does not prevent relapse in alcoholics. Result from a placebo-controlled study. Alcohol Alcoholism 36/4: 329–334
Withworth A, Fischer F, Lesch OM et al. (1996) Acamprosate versus placebo in the long term treatment of patients with alcohol dependence. Lancet 347: 1438–1442
Literatur
Allen JP, Litten RZ (2001) The role of laboratory testing in alcoholism treatment. J Subst Abuse Treatm 20: 81–85
Alling C, Gustavsson L, Änggård E (1983) An abnormal phospholipid in rat organs after ethanol. FEBS Lett 152: 24–28
Alt A, Janda I, Seidl S et al. (2000) Determination of ethyl glucuronide in hair samples. Alcohol Alcoholism 35: 313–314
Anton RF (2001) Pharmacologic approaches to the management of alcoholism. J Clin Psychiatry 62(S20): 11–17
Apter A, van Praag HM, Plutchik R et al. (1990) Interrelationships among anxiety, aggression, impulsivity and mood: a serotonergically linked cluster? Psychiatry Res 32: 191–199
Babor TF, Hofmann M, Delboca FK et al. (1992a) Types of alcoholics. I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 49: 599–608
Babor TF, Delboca FK, Kadden RM et al. (1992b) Types of alcoholics. II. Application of an empirically derived typology to treatment matching. Arch Gen Psychiatry 49: 609–614
Balldin J, Berggren U, Engel J et al. (1994) Effect of citalopram on alcohol intake in heavy drinkers. Alcohol Clin Exp Res 18: 1113–1136
Baumgarten HG (1991) Neuroanatomie und Neurophysiologie des zentralen 5-HT-Systems. In: Heinrich K, Hippius H, Pöldinger W (Hrsg) Serotonin — ein funktioneller Ansatz für die psychiatrische Diagnose und Therapie? Springer, Berlin Heidelberg New York Tokyo, S 17–44
Böning J (1991) Zur Neurobiologie und Psychopathologie süchtigen Verhaltens. In: Wanke K, Bühringer G (Hrsg) Grundstörungen der Sucht. Springer, Berlin Heidelberg New York Tokyo, S 1–27
Böning J (1994) Warum muss es ein „Suchtgedächtnis“ geben? Klinische Empirie und neurobiologische Argumente. Sucht 40: 244–252
Böning J (1996) Supportive medikamentöse Rückfallprophylaxe bei der Alkoholabhängigkeit. Ergebnisse kontrollierter Doppelblindstudien mit „Anticraving“-Substanzen. Nervenheilkunde 15: 72–79
Böning J (2001) Neurobiology of an addiction memory. J Neural Transm 108: 755–765
Böning J, Wiesbeck GA, Weijers H-G (2004) Biopsychological personality traits as predictors for relapse. Eur Arch Psychiatry Clin Neurosci 254[Suppl 1]: I/9
Bonnaffoux D, Jeanparis F, Bourgeat P et al. (1982) Follow-up treatment after alcohol withdrawal: results after two years in 200 cases. La semaine des hopitaux de Paris 58: 2079–2081
Borg S (1983) Bromocriptine in the prevention of alcohol abuse. Acta Psychiatr Scand 68: 100–110
Burling TA, Reilly PM, Moltzen JO et al. (1989) Self-efficacy and relapse among inpatient drug and alcohol abusers: a predictor of outcome. J Stud Alcohol 50: 354–360
Buydens-Branchey L, Branchey MH, Noumair D (1989) Age of alcoholism onset. I. Relationship to psychopathology. II. Relationship to susceptibility to serotonin precursor availability. Arch Gen Psychiatry 46: 225–230, 231–236
Cloninger CR (1987) A systematic method for clinical description and classification of personality variants: a proposal. Arch Gen Psychiatry 44: 573–588
Costall B, Jones BJ, Kelly ME et al. (1990) Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol Biochem Behav 36: 339–344
Dahl H, Stephanson N, Beck O et al. (2002) Comparison of urinary excretion characteristics of ethanol and ethyl glucuronide. J Anal Toxicol 26: 201–204
Dan L, Laposata M (1997) Ethyl palmitate and ethyl oleate are the predominant fatty acid ethyl esters in the blood after ethanol ingestion and their synthesis is differentially influenced by the extracellular concentrations of their corresponding fatty acids. Alcohol Clin Exp Res 21: 286–292
Delamaire D, Carpentier MC, Eudier F et al. (1986) Essai ambulatoire du tiapridal après sevrage alcoholique hospitalier. Etude randomisée de cinquante et une hépatopathies alcooliques en double insu. Le semaine des hopitaux de Paris 62: 3109–3114
Diczfalusy MA, Bjorkhem I, Einarsson C et al. (1999) Formation of fatty acid ethyl esters in rat liver microsomes. Evidence for a keyrole of acyl-CoA: ethanol O-acyltransferase. Eur J Biochem 259: 404–411
Dongier M, Vachon L, Schwartz G (1991) Bromocriptine in the treatment of alcohol dependence. Alcoholism: Clin Exp Res 15: 970–977
Ebstein RP, Nemanov L, Klotz I et al. (1997) Additional evidence for an association between the dopamine D4 receptor (D4DR) exon III repeat polymorphism and the human personality trait of novelty seeking. Mol Psychiatry 2: 472–477
Eriksson M, Berggren U, Blennow K et al. (2001) Further investigation of citalopram on alcohol consumption in heavy drinkers: responsiveness possibly linked to the DRD2 A2/A2 genotype. Alcohol Alcoholism 24: 15–23
Fallgatter A, Wiesbeck GA, Weijers H-G et al. (1998) Event-related correlates of response suppression as indicators of novelty seeking in alcoholics. Alcohol Alcoholism 33: 475–481
Favre JD, Guelfi-Sozzi C, Delalleau B et al. (1997) Tianeptine and alcohol dependence. Eur Neuropsychopharmacol 7: S 347–S351
Fawcett J, Kravitz HM, Mcguire M et al. (2000) Pharmacological treatments for alcoholism: revisiting lithium and considering buspirone. Alcohol Clin Exp Res 24: 666–674
Gastpar M, Rösinger C, Bender S (1993) A german multicenter study with tiapride in the long-term management of alcoholics. Pharmacopsychiatry 26: 154
George DT, Rawlings R, Eckardt MJ et al. (1999) Buspirone treatment of alcoholism: age of onset, and cerebrospinal fluid 5-hydroxyindolacetc acid and homovanillic acid concentrations, but not medication treatment, predict return to drinking. Alcohol Clin Exp Res 23: 272–278
Gilg T, Soyka M (1997) Wertigkeit biologischer Marker für Alkoholabusus und Alkoholismus. Nervenheilkunde 16: 362–371
Glaser T, Fassbender M, Mauler F (1998) Receptor binding of flupenthixol and other neuroleptics. PT06004, XXIst CINP Congress, Glasgow
Gorelick DA, Paredes A (1992) Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 16: 261–265
Graeff FL (1986) 5-Hydroxytryptamine, aversion and anxiety. Behav Brain Sci 9: 339–340
Hansson P, Caron M, Johnson G et al. (1997) Blood phosphatidylethanol of alcoholic abuse: levels in alcoholic males during withdrawal. Alcohol Clin Exp Res 21: 108–110
Helander A, Beck O, Jacobsson G et al. (1992) Characterization of elevated urinary 5-hydroxytryptophol as a marker of recent alcohol consumption. Alcohol Clin Exp Res 16: 607
Janiri L, Gobbi G, Mannelli P (1996) Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. Int Clin Psychopharmacol 11: 109–117
Johnson BA, Jasinski DR, Galloway GP et al. (1996) Ritanserin in the treatment of alcohol dependence — a multi-center clinical trial. Psychopharmacology 128: 206–215
Johnson BA (2000) Serotonergic agents and alcoholism treatment: rebirth of the subtype concept — a hypothesis. Alcohol Clin Exp Res 24: 1597–1601
Kabel DI, Petty F (1996) A placebo-controlled double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res 20: 780–784
Kiefer F, Jahn H, Holzbach R et al. (2003) Die NALCAM-Studie: Wirksamkeit, Verträglichkeit, Outcome. Sucht 49: 342–351
Kranzler HR, Burleson JA, Korner P et al. (1995) Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 152: 391–397
Kranzler HR, Burleson JA, Brown J et al. (1996) Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res 20: 1534–1541
Kranzler HR, Modesto-Lowe V, van Kirk J (2000) Naltrexone vs Nefazodone for treatment of alcohol dependence. A placebocontrolled trial. Neuropsychopharmacology 22: 493–503
Kranzler HR, Pierucci-Lagha A, Feinn R et al. (2003) Effects of ondansetron in early-versus late-onset al.coholics: a prospective, open-label study. Alcohol Clin Exp Res 27: 1150–1155
Laposata M (1999) Assessment of ethanol intake — current tests and new assays on the horizon. Am J Clin Pathol 112: 443–450
Lee MA, Meltzer HY (1991) Neuroendocrine responses to serotonergic agents in alcoholics. Biol Psychiatry 30: 1017–1030
Le Marquand D, Pohl RO, Benkelfat C (1994) Serotonin and alcohol intake, abuse and dependence. Clinical evidence. Biol Psychiatry 1994: 326–337
LEsch KP, Bengel D, Heils A et al. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527–1531
Lesch OM (1985) Chronischer Alkoholismus — Typen und ihr Verlauf. Eine Langzeitstudie. Thieme, Stuttgart New York
Lesch OM, Walter H (1996) Subtypes of alcoholism and their role in therapy. Alcohol Alcoholism 31[Suppl 1]: 63–67
Leysen JE, Gommeren W, van Gompel P et al. (1985) Receptor binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27: 600–611
Linnoila M, Eckardt M, Durcan M et al. (1987) Interactions of serotonin with ethanol: clinical and animal studies. Psychopharmacol Bull 23: 452–457
Malka R, Loo H, Ganry H et al. (1992) Long-term administration of tianeptine in depressed patients after alcohol withdrawal. Br J Psychiatry 160: 66–71
Malec E, Malec T, Gagne MA et al. (1996) Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Alcohol Clin Exp Res 20: 307–312
Meert TF, Janssen PAJ (1991) Ritanserin, a new therapeutic approach for drug abuse. Drug Dev Res 25: 39–53, 55–66
Meyer RE (1989) Prospects for a rational pharmacotherapy of alcoholism. J Clin Psychiatry 50: 403–412
Naranjo CA, Sellers EM, Roach CA et al. (1984) Zimelidine-induced variations in alcohol intake by nondrepressed heavy drinkers. Clin Pharmacol Ther 35: 374–381
Naranjo CA, Sellers EM, Sullivan JT et al. (1987) The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 41: 266–274
Naranjo CA, Sullivan JT, Kadlec K et al. (1989) Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clin Pharmacol Ther 46: 301–309
Naranjo CA, Kadlec K, Sanhueza P et al. (1990) Fluoxetine differentially alters alcohol intake and other consummatory behaviours in problem drinkers. Clin Pharmacol Ther 47: 490–498
Naranjo CA, Poulos CX, Bremner KE et al. (1992) Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther 51: 729–739
Naranjo CA, Poulos CX, Bremner KE et al. (1994) Fluoxetine attentuates alcohol intake and desire to drink. Int Clin Psychopharmacol 9: 163–172
Naranjo CA, Bremner KE, Lanctot KL (1995) Effects of citalopram on a brief psychosocial intervention on alcohol intake, dependence and problems. Addiction 90: 87–99
Naranjo CA, Dongier M, Bremner KE (1997) Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction 92: 969–978
Pettinati HM, Volpicelli JR, Luck G et al. (2001) Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 21: 143–153
Powell BJ, Campbell JL, Landon JF et al. (1995) A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. Alcohol Clin Exp Res 19: 462–468
Roy A, Vierkkunen M, Linnoila M (1987) Reduced central serotonin turnover in a subgroup of alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 11: 173–177
Sabourin A (1985) Effects of various therapeutic procedures on maintenance of abstinence in alcoholic patients: a statistical analysis. La semaine des hopitaux de Paris 61: 669–676
Saletu-Zylharz GM, Arnold O, Anderer P et al. (2004) Differences in brain fuction between relapsing and abstaining alcohol-dependent patients, evaluated by EEG-Mapping. Alcohol Alcoholism 39: 233–240
Schmidt LG, Dufeu P, Kuhn S et al. (1994) Relapse prevention in alcoholics with an anticraving drug treatment: first results of the Berlin study. Pharmacopsychiatry 27[Suppl 1]: 21–23
Schmidt LG, Dufeu P, Kuhn S et al. (1995) Perspektiven einer Pharmakotherapie der Alkoholabhängigkeit. Nervenarzt 66: 323–330
Schmidt LG, Kuhn S, Smolka M et al. (2002) Lisuride, a dopmine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence. Prog Neuropsychopharmacol Biol Psychiatry 26: 209–217
Schrappe O (1980) Toxikomanie. In: Peters UH (Hrsg) Die Psychologie des 20. Jahrhunderts, Bd X. Ergebnisse für die Medizin (2). Psychiatrie. Kindler, Zürich, S 849–86
Schuckit MA (1985) The clinical implications of primary diagnostic groups among alcoholics. Arch Gen Psychiatry 42: 1043–1049
Sellers EM, Toneatto R, Romach MK et al. (1994) Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 18: 879–885
Shaw GK, Majumdar SK, Waller S et al. (1987) Tiapride in the long-term management of alcoholics of anxious or depressive temperament. Br J Psychiatry 150: 164–168
Shaw GK, Waller S, Majumdar SK et al. (1994) Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 165: 515–523
Solomon KE, Annis HM (1990) Outcome and efficacy expectancy in the prediction of posttreatment drinking behaviour. Br J Addict 85: 659–665
Soyka M, Aichmueller C, v Bardeleben U et al. (2003) Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study. Eur Addict Res 9: 65–72
Tarter RE, Mcbride H, Buonpane N et al. (1977) Differentiation of alcoholics. Childhood history of minimal brain dysfunction, family history, and drinking pattern. Arch Gen Psychiatry 34: 761–768
Taylor DP, Rhines KC, Eison AS et al. (1995) Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 56: 3–11
Thomas R (1990) Fluvoxamine and alcoholism. Int Clin Psychopharmacol 6[Suppl 3]: 85–92
Thorner MO, Fluckiger E, Calne DB (1980) Bromocriptine. A clinical and pharmacological review. Raven Press, New York
Tiihonen J, Ryynanen OP, Kauhanen J et al. (1996) Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. Pharmacopsychiatry 29: 27–29
Tollefson GD (1989) Serotonin and alcohol: interrelationships. Psychopathology 22[Suppl]: 37–48
Toleffson GD, Lancaster SP, Montague-Clouse J (1991) The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmcol Bull 27: 163–170
Varga A, Hansson P, Lundqvist C et al. (1998) Phosphatidylethanol in blood as a marker of ethanol consumption in healthy volunteers: comparison with other markers. Alcohol Clin Exp Res 22: 1832–1837
Verheul R, van den Brink W, Geerlings P (1999) A three-pathway psychobiological model of craving for alcohol. Alcohol Alcoholism 34: 197–222
Weijers H-G, Wiesbeck GA, Jakob F et al. (2001) Neuroendocrine response to fenfluramine and its relationship to personality in alcoholism. J Neural Transm 108: 1093–1105
Weijers H-G, Wiesbeck GA, Wodarz N et al. (2003) Gender and personality in alcoholism. Arch Wom Ment Health 6: 245–252
Wiesbeck GA, Weijers HG, Chick J et al. (1999) Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Alcohol Clin Exp Res 23: 206–215
Wiesbeck GA, Weijers H-G, Lesch OM et al. (2001) Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol Alcoholism 36: 329–334
Wiesbeck GA, Weijers H-G, Wodarz N et al. (2003) Gender related differences in pharmacological relapse prevention with flupenthixol decanoate. Arch Wom Ment Health 6: 259–262
Wiesbeck GA, Weijers H-G, Wodarz N et al. (2004) Serotonin transporter gene polymorphism and personality traits in primary alcohol dependence. World J Biol Psychiatry 5: 42–45
Wolffgramm J, Heyne A (1995) From controlled drug intake to loss of control: the irreversible development of drug addiction in the rat. Behav Brain Res 70: 77–94
Wurst FM, Metzger JW on behalf of the WHO/ISBRA study on biological state and trait markers of alcohol use and dependence (2002) The direct ethanol metabolite ethyl glucuronide is a specific marker of recent alcohol consumption. Alcohol Clin Exp Res 26: 1114–1119
Wurst FM, Vogel R, Jachau K et al. (2003a) Ethyl glucuronide discloses recent covert alcohol use not detected by standard testing in forensic psychiatric inpatients. Alcohol Clin Exp Res 27: 471–476
Wurst FM, Skipper GE, Weinmann W (2003b) Ethyl glucuronide-the direct ethanol metabolite on the threshold from science to routine use. Addiction 98[Suppl 2]: 51–61
Wurst FM, Alexson S, Wolfersdorf M et al. (2004) Concentration of fatty acid ethyl esters in hair of alcoholics: comparison to other biological state markers and self reported ethanol intake. Alcohol Alcoholism 39: 33–38
Zuckerman M (1994) Behavioral expressions and biosocial bases of sensation-seeking. Cambridge University Press, New York
Literatur
Barrowclough C, Haddock G, Tarrier N et al. (2001) Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 158: 1706–1713
Borges G, Walters EE, Kessler RC (2000) Associations of substance use, abuse, and dependence with subsequent suicidal behavior. Am J Epidemiol 151: 781–789
Cacciola JS, Alterman AI, Rutherford MJ et al. (2001) The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend 61: 271–280
Covey LS, Glassman AH, Stetner F (1998) Cigarette smoking and major depression. J Addict Dis 17: 35–46
Covey LS, Glassman AH, Stetner F et al. (2002) A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Am J Psychiatry 159: 1731–1737
Dean AJ, Bell J, Mascord DJ et al. (2002) A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. J Affect Disord 72: 85–90
Farrell M, Howes S, Taylor C et al. (1998) Substance misuse and psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey. Addict Behav 23: 909–918
Griffiths RR, Wolf B (1990) Relative abuse liability of different benzodiazepines in drug abusers. J Clin Psychopharmacol 10: 237–243
Hansen SS, Munk-Jorgensen P, Guldbaek B et al. (2000) Psychoactive substance use diagnoses among psychiatric in-patients. Acta Psychiatr Scand 102: 432–438
Hunt GE, Bergen J, Bashir M (2002) Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 54: 253–264
Jacobsen LK, Southwick SM, Kosten TR (2001) Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry 158: 1184–1190
Kavanagh DJ, McGrath J, Saunders JB et al. (2002) Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 62: 743–755
Krystal JH, D’Souza DC, Madonick S et al. (1999) Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophr Res 35: S35–S49
Merikangas KR, Mehta RL, Molnar BE et al. (1998) Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav 23: 893–907
Murphy GE, Wetzel RD (1990) The lifetime risk of suicide in alcoholism. Arch Gen Psychiatry 47: 383–392
Raimo EB, Schuckit MA (1998) Alcohol dependence and mood disorders. Addict Behav 23: 933–946
Regier DA, Farmer ME, Rae DS et al. (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264: 2511–2518
Sherwood Brown E, Suppes T et al. (2001) Drug abuse and bipolar disorder: comorbidity or misdiagnosis? J Affect Disord 65: 105–115
Soyka M, Aichmuller C, Bardeleben U et al. (2003) Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study. Eur Addict Res 9: 65–72
Weiner E, Ball MP, Summerfelt A et al. (2001) Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 158: 635–637
Wodarz N, Johann M (2003) Veränderte Wirksamkeit von Arzneimitteln bei Suchterkrankungen. Arzneimitteltherapie 21: 336–341
Literatur
Athen D (1986) Comparative investigation of chlormethiazole and neuroleptic agents in the treatment of alcoholic delirium. Acta Psychiatr Scand 73: 167–170
Athen D, Hippius H, Meyendorf R et al. (1977) Ein Vergleich der Wirksamkeit von Neuroleptika und Chlormethiazol bei Behandlung des Alkoholdelirs. Nervenarzt 48: 528–532
BAnz-Nr. 116 (27. 06. 1991) ATC-Code: NO5CMO2, Monografie: Clomethiazol
Bayer AJ, Bayer EM, Pathy MSJ et al. (1986) A double-blind controlled study of chlormethiazole and triazolam as hypnotics in the elderly. Acta Psychiatr Scand 73: 104–111
Beckmann H, Athen D (1978) Die Therapie des Delirium tremens. Dtsch Med Wochenschr 103: 1427–1428
Calverley PMA, Carmichael GLM, Scott DB (1984) The effect of chlormethiazole on the hypoxic drive to breathing in normal man. Br J Clin Phamacol 18: 163–167
Douglas NJ, White DP, Weil JV et al. (1982) Hypoxic ventilatory response decrease during sleep in normal man. Am Rev Resp Dis 1235: 286–289
Evans J, Lewis SA, Tinker M (1972) Chlormethiazole, sleep an drug withdrawal. Psychol Med 2: 239–247
Feuerlein W (1989) Aktuelle Beiträge zur Definition und Therapie der Alkoholkrankheit. Neuropsychiatrie 3: 7–12
Fischer PA (1977) Intensivbehandlung des Alkoholentzugssyndroms. Diagnostik Intensivther 2: 9–11
Fritze J, Schmauss M, Holsboer F (2003) Was bedeutet die Vorschlagsliste verordungsfähiger Arzneimittel (sog. Positivliste) für die Psychopharmakatherapie? Nervenarzt 2: 195–197
Geisler I, Herberg D (1967) Studies on the effect of some commonly used drugs on the excitability of the respiratory centre in man. Therapiewoche 47: 1941–1947
Giacobini E, Salum I (1961) Treatment of delirium tremens. A comparative study of different therapeutic methods in 434 cases. Acta Psychiatr Scand 37: 198–208
Gsell S, Ossenkopp G, Weigeldt HD et al. (1972) Atem-und Herzstillstand unter Distraneurin. Nervenarzt 43: 635
Helbig H (1962) Das tödliche Alkoholdelir. Nervenarzt 33: 221–226
Hoensch HP (1986) Effect of chlormethiazole on the hepatic monooxygenase enzyme system. Acta Psychiatr Scand 73: 66–68
Holzbach E, Bühler KE (1978) Die Behandlung des Delirium tremens mit Haldol. Nervenarzt 49: 405–409
Hunnius Pharmazeutisches Wörterbuch, 8. Aufl (1998) de Gruyter, Berlin, S 344
Jostell KG, Agurell S, Hollister LE et al. (1978) Kinetics of chlormethiazole in patients with alcohol withdrawal manifestations. Clin Pharmacol: 181–187
Jostell KG, Mitchell RM, Scott DB et al. (1986) The bioavailability and pharmacodynamics of chlormethiazole in healthy young and elderly volunteers: preliminary findings. Acta Psychiatr Scand 73: 32–33
Jostell KG, Fagan D, Björk M et al. (1987) Pharmacokinetics of chlormethiazole in healthy young and elderly volunteers using stable isotope methodology. In: Jostell KG (ed) Pharmacokinetics of chlormethiazole in man and influence of altered physiological conditions. Thesis, University of Uppsala
Kalant H, Khanna JM (1986) Metabolic and functional aspects of tolerance to chlormethiazole and cross-tolerance to ethanol in the rat. Acta Psychiatr Scand 73: 45–53
Kalant H, Khanna JM, Liewellyn M et al. (1986) Functional tolerance to chlormethiazole and crosstolerance to ethanol in the rat: importance of test and mode of drug administration. Acta Psychiatr Scand 73: 54–65
Keup W (1977) Das Abhängigkeitspotential des Clomethiazol (Distraneurin). Dtsch Ärztebl 74: 1902–1905
Klotz U, Avant GR, Hoyumpa A et al. (1975) The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 55: 347–359
Koo KW, Sax DS, Snider GL (1975) Arterial blood gases and pH during sleep in chronic obstructive pulmonary disease. Am J Med 58: 663–670
Laborit H, Coirault R (1957) L’utilisation en clinique mèdicale et psychiatrique de Paction hypogène d’un dèrivè du moyan thiazolique de la Vitamine B1, Le S.C.T.Z. Sem Med (Paris) 33: 1704
Laborit H, Coirault R, Damasio R et al. (1957) Surun type nouveau d’anesthèsie chirugicale et sur e’emploi en thèrapeutique d’un dèpresseur du cortex cèrèbral. (S.C.T.Z.). Aneth Analg 14: 384
Laux G (2003a) Versorgung des akut verwirrten alten Menschen — eine interdisziplinäre Aufgabe/Akutbehandlung? Dtsch Ärztebl 100, Ausgabe 49: A-3253–A-3254
Laux G (2003b) Notfalltherapie. Fortschr Neurol Psychiatr 71: 483–501
Lesch OM, Walter H, in Zusammenarbeit Mit Gierth L, Leitner A, Platz WE, Zylharz G (1994) „Cutt off“-Punkte zur Bestimmung der Trinktypen nach Lesch, 2. Aufl. Vivantes, Berlin
Liljenberg B, Almquist M, Broman JE et al. (1986) The effects of chlormethiazole in EEG recorded sleep in normal elderly volunteers. Acta Psychiatr Scand 73: 34–39
Lucht M, Kuehn KU, Armbruster J et al. (2003) Alcohol withdrawal treatment in intoxicated vs non-intoxicaded patients: a controlled open-label study with tiapride/carbamazepine, clomethiazole and diazepam. Alcohol Alcoholism 38: 168–175
Majumdar SK (1978) The effect of chlormethiazole on hepatic microsomal enzymes. Pharmatherapeutica 2: 27–30
Majumdar SK (1981) Effects on the endocrine system of drugs used in treating the ethanol withdrawal syndrome: a survey. Drug Alcohol Depend 7: 379–385
Majumdar SK (1986) The influence of chlormethiazole on the neuroendocrine system in chronic alcoholics. Acta Psychiatr Scand 73:69–72
Maxion H, Schneider E (1970) Der Einfluss von Chlormethiazol (Distraneurin) auf das Schlaf-Elektroencephalogramm nach Alkoholdelir. Pharmakopsychiatr Neuro Psychopharm 3: 233–238
Möller HJ, Laux G, deister A (2001) Psychiatrie und Psychotherapie, 2. Aufl. Thieme, Stuttgart
Moore RG, Triggs EJ, Shanks CM et al. (1975a) Pharmacokinetics of chlormethiazole in humans. Eur J Clin Pharmacol 8: 353–357
Moore RG, Robertson AV, Smyth MP et al. (1975b) Metabolism and urinary excretion of chlormethiazole in humans. Xenobiotica 5: 687–696
Müller-Oerlinghausen B (2001) Abhängigkeit und Missbrauch von Substanzen. Dtsch Ärztebl 39,24: A-1625–A-1627
Nies AS, Shand PG, Wilkinson GR (1976) Altered hepatic blood flow and drug disposition. Clin Pharmacokinet 1: 135–155
Ögren SO (1986) Chlormethiazole-mode of action. Acta Psychiatr Scand 73: 13–27
Pälsson A (1986) The efficacy of early chlormethiazole medication in the prevention of delirium tremens. A retrospective study of the outcome of different drug treatment strategies at the Helsingborg Psychiatric Clinics, 1975–1980. Acta Psychiatr Scand 73: 140–145
Pentikäinen PJ, Neuvonen PJ, Jostell KG (1980) Pharmacokinetics of clormethiazole in healthy volunteers and patients with cirrhosis of the liver. Eur J Clin Pharmacol 17: 275–84
Platz W (1981) Therapie medikamentös bedingter deliranter Syndrome, insbesondere bei Clomethiazol-Abhängigkeit. In: Keup W (Hrsg) Behandlung der Sucht und des Missbrauchs chemischer Stoffe. 4. Wissenschaftliches Symposium, Deutsche Hauptstelle gegen die Suchtgefahren, Tutzing, 1980. Thieme, Stuttgart New York, S 65–73
Platz W (1985) Medikamentöse Therapie bei gerontopsychiatrischen Notfällen. Med Klin 80: 511–513
Schied HW, Mann K (1989) Die Behandlung des Delirium tremens und des Alkoholentzugssyndroms. In: Schied HW, Heimann H, Mayer K (Hrsg) Der chronische Alkoholismus. Fischer, Stuttgart New York, S 285–300
Schmehling E (1967) Atemdepression nach Distraneurin? Nervenarzt 38: 266–269
Schmidt L (1986) Alkoholkrankheit Alkoholmissbrauch. Kohlhammer, Stuttgart Berlin Köln Mainz
Scott DB (1986) Circulatory and respiratory effects of chlormethiazole. Acta Psychiatr Scand 73: 28–31
Stille G (1986) Das Abhängigkeitspotential von Clomethiazol. In: Evans G, Feuerlein W, Glatt MM et al. (Hrsg) Clomethiazol. Verlag für angewandte Wissenschaften, München, S 103–109
Swift CG, Procter AW (1994) Chlormethiazole, a clinical profile, rev edn. The Medicine Group, Abingdon
Who Expert Committe on Drug Dependence (1988) Twenty-fourth report. Technical Report Series 915. World Health Organization, Geneva, pp 11–13
Literatur
Al Quatari M, Bouchenafa O, Littleton J (1998) Mechanisms of action of acamprosate, part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 22: 810–814
Ansoms C, Deckers F, Lehert P et al. (2000) An open study with acamprosate in Belgium and Luxemburg: results on sociodemographcs, supportive treatment and outcome. Eur Addict Res 6: 132–140
Barrias JA, Chabac S, Ferreira L et al. (1997) Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatria Clinica 18: 149–160
Berglund M, Thelander S, Jonsson E (2003) Treating alcohol and drug abuse. An evidence based review. Wiley VCH Verlag, Weinheim
Besson J, Aeby F, Kasas A et al. (1998) Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 22: 573–579
Chick J, Howlett H, Morgan MY et al. (2000) United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35: 176–187
Engelhard K, Werner C, Lu H et al. (2000) The neuroprotective effect of the glutamate antagonist acamprosate following experimental cerebral ischemia. A study with the lipid peroxidase inhibitor u-101033e. Anaesthesist 49: 816–821
Geerlings P, Ansoms C, van den BRINK W (1995) Acamprosate and relapse prevention in outpatient alcoholics: results from a randomized, placebo-controlled double-blind study in the Netherlands, Belgium and Luxembourg. Eur Addict Res 3: 129–137
Gual A, Lehert P (2001) Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alohol 36: 413–418
Harris BR, Prendergast MA, Gibson DA et al. (2002) Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 26: 1779–1793
Kiefer F, Wiedemann K (2004) Zur differentiellen Indikationsstellung von Anti-Craving-Substanzen bei Alkoholabhänngigkeit. Nervenheilkunde 23: 521–526
Kiefer F, Jahn H, Tarnaske T et al. (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60: 92–99
Koob GF, Mason BJ, De Witte P et al. (2002) Potential neuroprotective effects of acamprosate. Alcohol Clin Exp Res 26: 586–592
Ladewig D, Knecht T, Leher P et al. (1993) Acamprosate — a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umsch 50: 182–188
Lhuintre JP, Daoust M, Moore ND et al. (1985) Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1: 1014–1016
Lhuintre JP, Moore N, Tran G et al. (1990) Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 25: 613–622
Littleton J, Zieglgänsberger W (2003) Pharmacological mechanisms of naltrexone and acam-prosate in the prevention of relapse in alcohol dependence. Am J Addict 12[Suppl 1]: S3–S11
Mann K (2004) Project PREDICT. Suchtforschungsverbund Baden-Württemberg. www.bw-suchtweb.de
Mann K, Lehert P, Morgan MY (2004) The efficacy of acamprosate in maintaining abstinence in alcohol dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 28: 51–63
Namkoong K, Lee B-O, Lee P-G et al. (2003) Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, doubleblind, placebo-controlled study. Alcohol Alcohol 38: 135–141
Paille FM, Guelfi JD, Perkins AC et al. (1995) Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 30: 239–247
Pelc I, Le Bon O, Verbanck P et al. (1992) Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients; a placebo controlled double-blind multi-centre study. In: Naranjo C, Sellers E (eds) Novel pharmacological interventions for alcoholism. Springer, New York, pp 348–352
Pelc I, Verbanck P, Le Bon O et al. (1997) Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 171: 73–77
Pelc I, Ansoms C, Lehert P et al. (2003) The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction. Alcohol Clin Exp Res 26: 1529–1538
Poldrugo F (1997) Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 92: 1537–1546
Rammes G, Mahal B, Putzke J et al. (2001) The anticraving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 40: 749–760
Rousseaux JP, Hers D, Ferauge M (1996) Does acamprosate influence alcohol consumption of weaned alcoholics? J Pharm Belg 51: 65–68
Sass H, Soyka M, Mann K et al. (1996) Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53: 673–680
Soyka M, Chick J (2003) Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: an European perspective. Am J Addict 12[Suppl 1]: S69–S80
Soyka M, Preuss U, Schuetz C (2002) Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results of a non-blind multicentre study. Drugs R D 3: 1–12
Spanagel R, Pendyala G, Abarca C et al. (2004) The circadian clock gene Period 2 influences the glutamatergic system and thereby modulates alcohol consumption. Nature Med 11: 35–42
Tempesta E, Janiri L, Bignamini A et al. (2000) Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebocontrolled study. Alcohol Alcohol 35: 202–209
Whitworth AB, Fischer F, Lesch OM et al. (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347: 1438–1442
Literatur
Altshuler HL, Phillips PA, Feinhandler DA (1980) Alternation of ethanol self-administration by naltrexone. Life Sci 26: 679–688
Anton RF, Moak DH, Waid R et al. (1999) Naltrexone and cognitive behavioral therapy of outpatient alcoholics: results of a placebocontrolled trial. Am J Psychiatry 156: 1758–1764
Anton RF, Moak DH, Latham PK et al. (2001) Posttreatment results of combining naltrexone and cognitive behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 21: 72–77
Balldin J, Berglund M, Borg S et al. (2003) A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alc Clin Exp Res 27: 1142–1149
Croop RS, Faulkner EB, Labriola DF (1997) The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 54: 1130–1135
Chick J, Anton R, Checinski K et al. (2000) A multicentre, randomised, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence in adults. Alcohol Alcohol 35: 587–593
Garbutt, JC, West SL, Carey TS et al. (1999) Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 281: 1318–1325
Gastpar M, Bonnet U, Boening J (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse. Results from a German multicenter study. J Clin Psychopharmacol 22: 592–598
Gillan MG, Kosterlitz HW, Paterson SJ (1980) Comparison of the binding characteristics of tritiated opiates and opioid peptides. Br J Pharmacol 70: 481–490
Guardia J, Caso C, ARIAS F et al. (2002) A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 26: 1381–1387
Hersh D, van Kirk JR, Kranzler HR (1998) Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology 139: 44–52
Heinälä P, Alho H, Kiianmaa K et al. (2001) Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 21: 287–292
Heinz A, Reimold M, Wrase J et al. (2005) Stable elevations in striatal μ-opioid receptor availability in detoxified alcoholics correlate with alcohol craving-a [11C] Carfentanil PET study. Arch Gen Psychiatry 62: 57–64
Jaffe AJ, Rounsaville B, Chang G et al. (1996) Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 64: 1044–1053
Kiefer F, Jahn H, Tarnaske T et al. (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60: 92–99
Kranzler HR, van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25: 1335–1341
Kranzler HR, Modesto-Lowe V, Nuwayser ES (1998) Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res 22: 1074–1079
Kranzler HR, Modesto-Lowe V, van Kirk JR (2000) Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 22: 493–503
Krystal JH, Cramer JA, Krol WF et al. (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345: 1734–1739
Latt NC, Jurd S, Houseman J et al. (2002) Naltrexone in alcohol dependence: a randomized controlled trial of effectiveness in a standard clinical setting. Med J Aust 176: 530–534
Lee MC, Wagner HN, Tanada S et al. (1988) Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 29: 1207–1211
Magnan J, Paterson SJ, Tavani A et al. (1982) The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn Schmiedebergs Arch Pharmacol 319: 197–205
Mann K (2004) Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs 18: 485–504
Mann K, Lehert P, Morgan MY (2004) The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 28: 51–63
Mccaul ME, Wand GS, Eissenberg T et al. (2000) Naltrexone alters subjective responses to alcohol in heavy drinking subjects. Neuropsychopharmacology 22: 80–492
Monterosso JR, Flannery BA, Pettinati HM et al. (2001) Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10: 258–268
Monti PM, Rohsenow DJ, Hutchison KE et al. (1999) Naltrexone’s effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 23: 1386–1394
Monti PM, Rohsenow DJ, Swift RM et al. (2001) Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 25: 1634–1647
Morris PL, Hopwood M, Whelan G et al. (2001) Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 96: 1565–1573
O’Brien C (2005) Naltrexone: clinical data. In: Spanagel R, Mann K (eds) Drugs for relapse prevention of alcoholism. Birkhäuser, Basel
O’Malley SS, Jaffe AJ, Chang G et al. (1992) Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49: 881–887
O’Malley SS, Jaffe AJ, Chang G et al. (1996) Sixmonth follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 53: 217–224
Oslin D, Liberto JG, O’Brien J et al. (1997) Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 5: 324–332
Rohsenow DJ, Colby SM, Monti PM et al. (2000) Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res 24: 1542–1549
Sinclair JD (2001) Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol 36: 2–10
Smolka MN, Kiefer R, Mann K (2003) Fortschritte in der Behandlung von Alkoholabhänngigen: die medikamentöse Rückfallprophylaxe. MMW Fortschr Med 145: 65–69
Soyka M (siehe Kap. 4.4.1 in diesem Band, Riederer, zu Acamprosat)
Srisurapanont M, Jarusuraisin N (2003) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 3: CD001867
Streeton C, Whelan G (2001) Naltrexone, a relapse-prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 36: 544–552
Volpicelli JR, O’Brien CP, Alterman AI et al. (1990) Naltrexone and the treatment of alcohol dependence: initial observations. In: Reid LB (ed) Opioids, bulimia, alcohol abuse and alcoholism. Springer, New York, pp 195–214
Volpicelli JR, Alterman AI, Hayashida M (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876–880
Volpicelli JR, Rhines KC, Rhines JS et al. (1997) Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54: 737–742
Literatur
Azrin NH, Sisson RW, Meyer SR et al. (1982) Alcoholism treatment by disulfiram and community reinforcement therapy. J Behav Ther Exp Psychiatry 13: 105–112
Bartmann U, Fautsch J (1991) Eine Chance für die ambulante Therapie. Psycho 17: 192–202
Bartonicek V, Teisinger J (1962) Effect of tetraethyl thiuram disulphide (disulfiram) on metabolism of trichloro-ethylene in man. Br J Industr Med 19: 216–221
Bilbao JM, Briggs SJ, Gray TA (1984) Filamentous axonopathy in disulfiram neuropathy. Ultrastruct Pathol 7: 295–300
Chick J, Gough K, Falkowski W et al. (1992) Disulfiram treatment of alcoholism. Br J Psychiatry 161: 84–89
Christensen JK, Ronsted P, Vaag VH (1984) Side effects after disulfiram. Acta Psychiatr Scand 69: 265–273
Ciraulo DA, Barnhill J, Boxenbaum H (1985) Pharmacokinetic interaction of disulfiram and antidepressants. Am J Psychiatry 142: 1373–1374
Coger RW, Dymond AM, Serafetinides EA et al. (1976) Averaged visual evoked response amplitude-intensity slope and symmetry in withdrawal. Biol Psychiatry 11: 435–443
Cushmann P (1986) Sedative drug interactions of clinical importance. In: Galanter M (ed) Alcoholism, vol 4. Plenum Press, New York London
Feuerlein W (1989) Alkoholismus — Mißbrauch und Abhängigkeit, 4. Aufl. G Thieme, Stuttgart
Fischer I (1945) Säregen svampförgiftining. Sv Läk-Tidn 42: 2513–2515
Fuller RK (1988) Disulfiram treatment of alcoholism. In: Rose RM, Barret JE (eds) Alcoholism: origins and outcome. Raven Press, New York, pp 237–244
Fuller RK, Roth HP (1979) Disulfiram for the treatment of alcoholism: an evaluation in 128 men. Ann Intern Med 90: 901–904
Fuller RK, Williford WO (1980) Life-table analysis of abstinence in a study evaluating the efficacy of disulfiram. Alcohol Clin Exp Res 4: 298–301
Gill K, Amit Z (1989) Serotonin uptake blockers and voluntary alcohol consumption. A review of recent studies. In: Galanter M (ed) Alcoholism, vol 7. Plenum Press, New York London, pp 225–248
Hald E, Jacobson I (1948) A drug sensitising the organism to ethylalcohol. Lancet ii: 1001–1003
Haubroe K (1980) What we know today about “Antabuse® (Disulfiram)”. Manedsskrift for praktisk Laegegerning 58: 30–40
Iber FL, Lee K, Lacoursiere R et al. (1987) Liver toxicity encoutered in the Veterans Administration trial of disulfiram in alcoholics. Alcohol Clin Res 11: 301–304
Jacobsen E (1967a) Neues über die theoretische Grundlage der Disulfiram-Wirkung. Med Welt 18(N.F.): 2169–2173
Jacobsen E (1967b) Die Verwendung von Disulfiram (Antabuse®). Med Welt 18 (N.F.): 2230–2234
Jaffe JH, Ciraulo DA (1985) Drugs used in the treatment of alcoholism. In: Mendelson JH, Mello NK (eds) The diagnosis and treatment of alcoholism, 2nd edn. McGraw-Hill, New York
Jensen E (1984) A proper use of Antabuse, the Danish model of treatment. Br J Clin Pract [Suppl 36] 38: 2–4
Kingsbury SJ, Salzman C (1990) Disulfiram in the treatment of alcoholic patients with schizophrenia. Hosp Commun Psychiatry 41: 133–134
Kitson TM (1977) The disulfiram-ethanol reaction. J Stud Alcohol 38: 96–113
Koelsch F (1914) Über neuartige gewerbliche Erkrankungen in Kalkstickstoffbetrieben. Münch Med Wochenschr 35: 1869–1870
Koivusalo M (1956) Studies on the metabolism of methanol and formaldehyde in the animal organism. Acta Physiol Scand 39[Suppl 131]
Küfner H, Feuerlein W (1989) In-patient treatment for alcoholism. Springer, Berlin Heidelberg New York Tokyo
Lenz H (1957) Zur Ursache der fehlenden Antabus-Alkohol-Reaktion. Wien Klin Wochenschr 38/39: 743
Lindros KO, Stowell A, Pikkarainen P et al. (1981) The disulfiram (Antabuse) alcohol reaction in male alcoholics: its efficient management by 4-methylpyrazole. Alcohol Clin Exp Res 5: 528–530
Macleod SM, Sellers EM, Giles HG et al. (1978) Interaction of disulfiram with benzodiazepines. Clin Pharmacol Ther 24: 583–589
Mccrady B (1989) Outcomes of family-involved alcoholism treatment. In: Galanter M (ed) Alcoholism, vol 7. Plenum Press, New York London, pp 165–182
Nutt D, Adinoff B, Limoila M (1989) Benzodiazepines in the treatment of alcoholism. In: Galanter M (ed) Alcoholism, vol 7. Plenum Press, New York London, pp 283–313
Pattison EM (1985) The selection of treatment modalities for the alcoholic patient. In: Mendelson JH, Mello NK (eds) The diagnosis and treatment of alcoholism, 2nd edn. McGraw-Hill, New York
Peeke SC, Prael AR, Herning RI et al. (1979) Effect of disulfiram on cognition, subjective response, and cortical event-related alcoholic in nonalcoholic subjects. Alcohol Clin Exp Res 3: 223–229
Perman ES (1962) Effect of ethanol on oxygen uptake and on blood glucose concentration in anesthetized rabbits. Acta Physiol Scand 55: 189–202
Platz WE (1995) Alkoholkriminalität. In: Schaffstein F, Schöch H, Schüler-Springorum H (Hrsg) Neue kriminologische Studien, Bd 12. Fink, München
Rainey JM (1977) Disulfiram toxicity and carbon disulfide poisoning. Am J Psychiatry 134: 371–378
Robichaud C, Strickler D, Bigelow G et al. (1979) Disulfiram maintenance employee alcoholism treatment: a three-phase evaluation. Behav Ther 14: 618–621
Schmidt L (1986) Alkoholkrankheit und Alkoholmißbrauch. Kohlhammer, Stuttgart
Schuckit MA (1981) Disulfiram (Antabuse) and the treatment of alcoholic men. Adv Alcohol 11: 1–4
Schuckit MA (1985a) Treatment of alcoholism in offices and outpatient settings. In: Mendelson JH, Mello NK (eds) The diagnosis and treatment of alcoholism, 2nd edn. McGraw-Hill, New York
Schuckit MA (1985b) A one-year follow-up of men alcoholics given disulfiram. J Stud Alcohol 46: 191–195
Schuckit MA (1985c) Inpatient and residential approaches to the treatment of alcoholism. In: Mendelson JH, Mello NK (eds) The diagnosis and treatment of alcoholism, 2nd edn. Mc-Graw-Hill, New York
Schuckit MA (1989) Drug and alcohol abuse. Plenum, New York London
Sellers EM, Naranjo CA, Peachey JE (1981) Drugs to decrease alcohol consumtion. N Engl J Med 305: 1255–1262
Staub H (1955) Beiträge zum Antabuse-Problem. Helv Physiol Acta 13: 121–140
Strömme JH, Eldjarn L (1966) Distribution and chemical forms of diethyldithiocarbamate and tetraethylthiuram disulphide (Disulfiram) in mice in relation to radioprotection. Biochem Pharmacol 15: 287–297
Truitt EB, Duritz G, Morgan AM et al. (1962) Disulfiram-like actions produced by hypoglycemic sulfonylurea compounds. Q J Stud Alcohol 23: 197–207
Usdin GL, Rond PC, Hinchcliffe JA et al. (1952) The meaning of disulfiram to alcoholics in group psychotherapy. Q J Stud Alcohol 13: 590–599
Volpicelli JR, Altermann AI, Hayashida M et al. (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876–880
Walter H, Nimmerrichter A, Mader R et al. (2002) Double blind controlled trial of GHB and clomethiazole in the tratment of alcohol withdrawal. Alcohol Alcoholism 37: 67–73
Willams EE (1937) Effects of alcohol on workers with carbon disulfide. JAMA 109: 1472–1473
Literatur
Agosti V (1995) The efficacy of treatments in reducing alcohol consumption: a meta-analysis. Int J Addict: 1067–1077
Ajima M, Usuki K, IGarashi A et al. (1997) Cyanamide-induced granulcytopenia. Intern Med 36: 640–642
Azrin NH (1976) Improvements in the community-reinforcement approach to alcoholism. Behav Res Ther 14: 339–348
Azrin NH, Sisson RW, Meyers R et al. (1982) Alcoholism treatment by disulfiram and community reinforcement therapy. J Behav Ther Exp Psychiat 13: 105–112
Besson J, Aeby F, Kasas A et al. (1998) Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcoholism: Clin Exp Res 22: 573–579
Bevilacqua JA, Diaz M, Diaz V et al. (2002) Neuropatía por disulfiram. Comunicación de tres casos clinicos. Rev Med Chil 130: 1037–1042
Brewer C (2003) Cyanamide or disulfiram in the treatment of adolescent alcohol misusers. Alcohol Alcoholism 38: 442–445
Carroll KM, Nich C, Ball SA et al. (2000) One year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction 95: 1325–1349
Carroll KM, Fenton LR, Ball SA et al. (2004) Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 61: 264–272
Chick J (1999) Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 20: 427–435
Christensen JK, Moeller IW, Ronstedt P et al. (1991) Dose-effect relationship of disulfiram in human volunteers. I. Clinical studies. Pharmacol Toxicol 68: 163–165
Demaster EG, Redfern B, Nagasawa HT (1998) Mechanism of inhibiton of aldehyde dehydrogenase by nitroxyl, the active metabolite of the alcohol deterrent agent cyanamide. Biochem Pharmacol 55: 2007–2015
Desousa A, Desousa A (2004) A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence. Alcohol Alcoholism 39: 528–531
Ehrenreich H, Mangholz A, Schmitt M et al. (1997) OLITA: an alternative in the treatment of therapy-resistant chronic alcoholics. First evaluation of a new approach. Eur Arch Psychiatry Clin Neurosci 247: 51–54
Foddai M, Dosia G, Spiga S et al. (2004) Acetaldehyde increases dopaminergic neuronal activity in the VTA. Neuropsychopharmacology 29: 530–536
Frisoni GB, di Monda V (1989) Disulfiram neuropathy: a review (1971–1988) and report of a case. Alcohol Alcoholism 24: 429–437
Fuller RK Branchey L, Brightwell DR et al. (1986) Disulfiram treatment of alcoholism: a veterans administration coorporative study. J Am Med Assoc 256: 1449–1455
Fuller RK, Gordis E (2004) Does disulfiram treatment have a role in alcoholism treatment today. Addiction 99: 21–24
Gessner PK, Gessner T (1992) Disulfiram and its metabolite diethylthiocarbamate. Chapman & Hall, London Glasgow New York Tokyo Melbourne Madras
Helander A, Tottmar O (1988) Effects of disulfiram, cyanamide and 1-aminocyclopropanol on the aldehyde dehydrogenase in human erythrocytes and leukocytes. Pharmacol Toxicol 63: 262–265
Jacobsen E (1952) Deaths of alcoholic patients treated with disulfiram (tetraethylthiuram disulfide) in Denmark. Q J Stud Alcohol 13: 16–26
Jacobsen E, Martensen-Larsen O (1949) Treatment of alcoholism with tretraethylthiuram disulfide (Antabus). J Am Med Assoc 139: 918–922
Jacobsen E (1987) The road to antabuse. Dumex, Copenhagen
Johnsen J, Stowell A, Stensrud T et al. (1990) A double-blind placebo controlled study of healthy volunteers given a subcutanous disulfiram implant. Pharmacol Toxicol 66: 227–230
Landabaso MA, Iraurgi I, Sanz J et al. (1999) Naltrexone in the treatment of alcoholism: two year follow-up results. Eur J Psychiatry 13: 97–105
Lewis MJ, Bland RC, Baile W (1975) Disulfiram implantation for alcoholism. Can Psychiatr Assoc J 20: 283–286
Liddon SC, Satran R (1967) Disulfiram (Antabuse) psychosis. Am J Psychiatry 123: 1284–1289
Lindros KO, Stowell A, Pekkarainen P et al. (1981) The disulfiram(antabuse)-alcohol reaction in male alcoholics: its efficient management by 4-methylpyrazole. Alcohol Clin Exp Res 5: 528–530
Madan A, Parkinson A, Faiman MD (1998) Indentification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldiethiocarbamate methyl ester: role of P-450 enzymes in disulfiram biocativation. Alcohol Clin Exp Res 22: 1212–1219
Marie C (1955) A propos d’un nouveau mode de traitement de l’alcoolism chronique par implantation de disulfure de tétra-éthyl-thiurame. Thèse, Paris
Martensen-Larsen O (1948) Nye linier i alkoholist-behandlingen. Ugeskr Laeg 110: 1207–1213
Martin B, Clapp L, Bialkowsky D et al. (2003) Compliance to supervised disulfiram therapy: a comparison of voluntary and court-ordered patients. Am J Addict 12: 137–143
Martin B, Alfers J, Kulig C et al. (2004) Disulfiram therapy in patients with hepatitis C: a 12-month, controlled, follow-up study. J Stud Alcohol 65: 651–657
Mørland J, Johnsen J, Bache-Wiig JE et al. (1985) Implanted disulfiram: pharmacological and clinical studies in man. In: Pharmacological treatment of alcoholism: withdrawal and aversion therapy. Socialstyreslsens Lakemedelsavdelning, Uppsala, pp 89–98
Mueser KT, Noordsy DL, Fox L et al. (2003) Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 12: 242–252
Niederhofer H, Staffen W, Mair A (2003) Comparison of cyanamide and placebo in the treatment of alcohol dependence of adolescents. Alcohol Alcoholism 38: 50–53
Petersen EN (1989) Pharmacological effects of diethylthiocarbamic acid methyl ester, the active metaboliter of disulfiram? Eur J Pharmcol 1966: 419–425
Poikolainen K (2004) The Disulfiram-Ethanol Reaction (DER) experience. Addiction 99: 26
Rodd-Henricks ZA, Melendez RI, Zaffaroni A et al. (2002) The reinforcing effects of acetaldehyde in the posterior ventral tegmental area of alcohol preffering rats. Pharmacol Biochem Behav 72: 55–64
Sisson RW, Azrin NH (1986) Family-member involvement to initiate and promote treatment of problem drinkers. J Behav Ther Exp Psychiat 17: 15–21
Sauna ZE, Peng XH, Nandigama K et al. (2004) The molecular basis of the action of disulfiram as a modulator of the multiple resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Mol Pharmacol 65: 675–684
Tamai H, Yokoyama A, Okuyama K et al. (2000) Comparison of cyanamide and disulfiram in effects on liver function. Alcohol Clin Exp Res 24[Suppl]: 97S–99S
Verheul R, Lehert P, Geerlings PJ et al. (2005) Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology 178: 167–173
Wagner T, Krampe H, Stawicki S et al. (2004) Substantial decrease of psychiatric comobidity in chronic alcoholics upon integrated outpatient treatment — results of a prospective study. J Psychiatr Res 38: 619–635
Wright C, Vafir JA, Lake C (1988) Disulfiram induced fulminating hepatitis: guidelines for liver-panel monitoring. J Clin Psychiatry 49: 430–434
Literatur
Addolorato G, Caputo F, Capristo E et al. (2002) Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 37: 504–508
Anand A, Charney DS, Cappiello A et al. (2000) Lamotrigine attenuates ketamine effects in humans: support for hyperglutamatergic effects of NMDA antagonists. Arch Gen Psychiatry 57: 270–276
Anstrom KK, Cromwell HC, Markowski T et al. (2003) Effect of baclofen on alcohol and sucrose self-administration in rats. Alcohol Clin Exp Res 27: 900–908
Altamura AC, Regazzetti MG, Porta M (1990) Nimodipine in human alcohol withdrawal syndrome — an open study. Eur Neuropsychopharmacol 1: 37–40
Bienkowski P, Stefanski R, Kostowski W (1997) Discriminative stimulus effects of ethanol: lack of antagonism with N-methyl-D-aspartate and D-cycloserine. Alcohol 14: 345–350
Bienkowski P, Krzascik P, Koros E et al. (2001) Effects of a novel uncompetitive NMDA receptor antagonist, MRZ 2/579 on ethanol selfadministration and ethanol withdrawal seizures in the rat. Eur J Pharmacol 413: 81–89
Blanpied TA, Boeckman FA, Aizenman E et al. (1997) Trapping channel block of NMDAactivated responses by amantadine and memantine. J Neurophysiol 77: 309–323
Bleich S, Degner D, Wiltfang J et al. (2000a) Elevated homocysteine levels in alcohol withdrawal. Alcohol Alcohol 35: 351–354
Bleich S, Degner D, Bandelow B et al. (2000b) Plasma homocysteine is a predictor of alcohol withdrawal seizures. Neuroreport 11: 2749–2752
Bleich S, Bandelow B, Javaheripour K et al. (2003a) Hyperhomocysteinemia as a new risk factor for brain shrinkage in patients with alcoholism. Neurosci Lett 335: 179–182
Bleich S, Römer K, Wiltfang J et al. (2003b) Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry 18[Suppl 1]: S33–S40
Bleich S, Degner D, Sperling W et al. (2004) Homocysteine as a neurotoxin in chronic alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 28: 453–464
Böning JAL, Lesch OM, Spanagel R et al. (2001) Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials. Alcohol Clin Exp Res 25: 127S–131S
Bouvier M, Szatkowski M, Amato A et al. (1992) The glial cell glutamate uptake carrier countertransports pH-changing anions. Nature 360: 471–474
Bustos GA, Abarca J, Forray MI et al. (1992) Regulation of excitatory amino acid release by N-methyl-D-aspartate receptors in rat striatum: in vivo microdialysis studies. Brain Res 585: 105–115
Carboni S, Isola R, Gessa GL et al. (1993) Ethanol prevents the glutamate release induced by N-methyl-D-aspartate in the rat striatum. Neurosci Lett 152: 133–136
Chen X, Michaelis MR, Michaelis EK (1997) Effects of chronic ethanol treatment on the expression of calcium transport carriers and NMDA receptor proteins in brain synaptic membranes. J Neurochem 69: 1559–1569
Chen HS, Pellegrini JW, Aggarwal SK et al. (1992) Open-channel block of N-methyl-Daspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 12: 4427–4436
Clements JD, Lester RAJ, Tong G et al. (1992) The time course of glutamate in the synaptic cleft. Science 258: 1498–1501
Colombo G, Agabio R, Carai MA et al. (2000) Ability of baclofen in reducing alcohol intake and withdrawal severity. I. Preclinical evidence. Alcohol Clin Exp Res 24: 58–66
D’Souza DC, Charney DS, Krystal JH (1995) Glycine site agonists of the NMDA receptor: a review. CNS Drug Rev 1: 227–260
D’Souza DC, Gil R, Cassello K et al. (2000) IV Glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry 47: 450–462
Danysz W, Janowska E, Glazewsky S et al. (1992) The involvement of NMDA receptors in acute and chronic effects of ethanol. Alcohol Clin Exp Res 16: 499–504
Davidson M, Shanley B, Wilce PA (1995) Increased NMDA-induced excitability during ethanol withdrawal: a behavioural and histological study. Brain Res 674: 91–96
Durand GM, Bennett MV, Zukin RS (1993) Splice variants of the N-methyl-D-aspartate receptor NR1 identify domains involved in regulation by polyamines and protein kinase C. Proc Natl Acad Sci USA 90: 6731–6735
Follesa P, Ticku MK (1996) Chronic ethanolmediated up-regulation of the N-methyl-Daspartate receptor polypeptide. J Biol Chem 271: 13297–13299
Garbutt JC, West SL, Carey TS et al. (1999) Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 281: 1318–1325
Gonzales R, Bungay PM, Kiianmaa K et al. (1996) In vivo links between neurochemistry and behavioral effects of ethanol. Alcohol Clin Exp Res 20: 203A–205A
Green KL, Grant KA (1999) Effects of L-type voltage-sensitive calcium channel modulators on the discriminative stimulus effects of ethanol in rats. Alcohol Clin Exp Res 23: 806–814
Harris RA, Valenzuela CF, Brozowski S et al. (1998) Adaptation of δ-aminobutyric acid type A receptors to alcohol exposure: studies with stably transfected cells. J Pharmacol Exp Ther 284: 180–188
Hodge CW, Cox AA (1998) The discriminative stimulus effects of ethanol are mediated by NMDA and GABAA receptors in specific limbic brain regions. Psychopharmacology 139: 95–107
Hoffman PL, Rabe CS, Grant KA et al. (1990) Ethanol and the NMDA receptor. Alcohol 7: 229–231
Hölter SM, Danysz W, Spanagel R (1996) Evidence for alcohol anti-craving properties of memantine. Eur J Pharmacol 314: 1–2
Hölter SM, Danysz W, Spanagel R (2000) Novel uncompetitive N-Methyl-D-Aspartate (NMDA)-receptor antagonist MRZ 2/579 suppresses ethanol intake in long-term ethanol-experienced rats and generalizes to ethanol cue in drug discrimination procedure. J Pharmacol Exp Ther 292: 545–552
Hundt W, Danysz W, Hölter SM et al. (1998) Ethanol and N-methyl-D-aspartate receptor complex interactions: a detailed drug discrimination study in the rat. Psychopharmacology 135: 44–51
Iorio KR, Reinlib L, Tabakoff B et al. (1992) Chronic exposure of cerebellar granule cells to ethanol results in increased N-methyl-Daspartate receptor function. Mol Pharmacol 41: 1142–1148
Javitt DC, Frusciante MJ, Zukin SR (1990) Rat brain N-methyl-D-aspartate receptors require multiple molecules of agonist for activation. J Pharmacol Exp Ther 37: 603–607
Javitt DC, Sershen H, Hashim A et al. (1997) Reversal of phencyclidine-induced hyperactivity by glycine and the glycine up-take inhibitor glycyldodecylamide. Neuropsychopharmacology 17: 202–204
Johnson BA, Roache JD, Javors MA et al. (2000) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients-a randomized controlled trial. JAMA 284: 963–971
Johnson BA, Ait-Daoud N, Bowden CL et al. (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361: 1677–1685
Kashiwagi K, Masuko T, Nguyen CD et al. (2002) Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore. Mol Pharmacol 61: 533–545
Kornhuber J, Weller M (1995) Predicting psychotomimetic properties of PCP-like NMDA receptor antagonists. In: Fog R, Gerlach J, Hemmingsen R (eds) Schizophrenia-Alfred Benzon Symposium. Munksgaard, Copenhagen, pp 314–325
Kornhuber J, Weller M (1997) Psychotogenicity and NMDA receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41: 135–144
Kornhuber J, Bleich S (1999) Memantin. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka, Bd 5, 2. Aufl. Springer, Wien New York, S 687–704
Kornhuber J, Bormann J, Retz W et al. (1989) Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166: 589–590
Kornhuber J, Bormann J, Hübers M et al. (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptorgated ion channel: a human postmortem brain study. Eur J Pharmacol Mol Pharmacol Sect 206: 297–300
Kornhuber J, Schoppmeyer K, Riederer P (1993) Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex. Neurosci Lett 163: 129–131
Kornhuber J, Weller M, Schoppmeyer K et al. (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm [Suppl 43]: 91–104
Kornhuber J, Retz W, Sitzmann L et al. (1996) The NMDA-receptor antagonist memantine is not psychotomimetic in young healthy volunteers. Soc Neurosci Abstr 22: 178
Kostowski W, Bienkowski P (1999) Discriminative stimulus effects of ethanol: neuropharmacological characterization. Alcohol 17: 63–80
Kotlińska J (2001) NMDA antagonists inhibit the development of ethanol dependence in rats. Pol J Pharmacol 53: 47–50
Krupitsky EM, Burakov AM, Romanova TN et al. (2001) Attenuation of ketamine effects by nimodipine in recently detoxified ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. Neuropsychopharmacology 25: 936–947
Krystal JH, Karper LP, Seibyl JP et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199–214
Krystal JH, Petrakis IL, Mason G et al. (2003) N-methyl-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther 99: 79–94
Kumari M, Ticku MK (2000) Regulation of NMDA receptors by ethanol. Prog Drug Res 54: 151–189
Kurth C, Wegerer V, Degner D et al. (2001) Risk assessment of alcohol withdrawal seizures with a Kohonen Feature Map. NeuroReport 12: 45–49
Liljequist S (1991) The competitive NMDA receptor antagonist, CGP-39551, inhibits ethanol withdrawal seizures. Eur J Pharmacol 192: 197–198
Lipton SA, Rosenberg PA (1994) Excitatory amino acids as a final common pathway for neurological disorders. N Engl J Med 330: 613–622
Lovinger DM, White G, Weight FF (1989) Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 243: 1721–1724
Luby ED, Cohen BD, Rosenbaum G et al. (1959) Study of a new schizophrenomimetic drug — sernyl. Arch Neurol Psychiatry 81: 363–369
Maler JM, Esselmann H, Wiltfang J et al. (2005) Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons (submitted)
Malinowska B, Napiorkowska-Pawlak D, Pawlak R et al. (1999) Ifenprodil influences changes in mouse behaviour related to acute and chronic ethanol administration. Eur J Pharmacol 377: 13–19
Marks SS, Watson DL, Carpenter CL et al. (1989) Calcium channel antagonist receptors in cerebral cortex from alcoholic patients. Brain Res 478: 196–198
Mason BJ, Kocsis JH, Ritvo EC et al. (1996) A doubleblind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 275: 761–767
Maurice T, Casalino M, Lacroix M et al. (2003) Involvement of the sigma1 receptor in the motivational effects of ethanol in mice. Pharmacol Biochem Behav 74: 869–876
Meldrum BS (2000) Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr [Suppl] 130: 1007–1015
Meyer RC, Knox J, Purwin DA et al. (1998) Combined stimulation of the glycine and polyamine sites of the NMDA receptor attenuates NMDA blockade-induced learning deficits of rats in a 14-unit T-maze. Psychopharmacology 135: 290–295
Miller NS (1995) Pharmacotherapy in alcoholism. J Addict Dis 14: 23–46
Miyazaki J, Nakanishi S, Jingami H (1999) Expression and characterization of a glycine-binding fragment of the N-methyl-D-aspartate receptor subunit NR1. Biochem J 340: 687–692
Moghaddam B, Bolinao M (1994) Biphasic effects of ethanol on extracellular accumulation of glutamate in the hippocampus and the nucleus accumbens. Neurosci Lett 178: 99–102
Moriyoshi K, Masu M, Ishii T et al. (1991) Molecular cloning and characterization of the rat NMDA receptor. Nature 354: 31–37
Morrisett RA, Rezvani AH, Overstreet D et al. (1990) MK-801 potently inhibits alcohol withdrawal seizures in rats. Eur J Pharmacol 176: 103–106
Nagy J, Horvath C, Farkas S et al. (2004) NR2B subunit selective NMDA antagonists inhibit neurotoxic effect of alcohol-withdrawal in primary cultures of rat cortical neurones. Neurochem Int 44: 17–23
Nestler EJ (2001) Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2: 119–128
Okabe S, Vicario-Abejon C, Segal M et al. (1998) Survival and synaptogenesis of hippocampal neurons without NMDA receptor function in culture. Eur J Neurosci 10: 2192–2198
Parsons CG, Gruner R, Rozental J et al. (1993) Patch clamp studies on the kinetic and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32: 1337–1350
Parsons CG, Quack G, Bresink I et al. (1995) Comparison of the potency, kinetics and voltage-dependency of open channel blockade for a series of uncompetitive NMDA antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34: 1239–1258
Parsons CG, Danysz W, Quack G (1998) Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11: 523–569
Peoples RW, Weight FF (1995) Cutoff in potency implicates alcohol inhibition of N-methyl-Daspartate receptors in alcohol intoxication. Proc Natl Acad Sci USA 92: 2825–2829
Peoples RW, White G, Lovinger DM et al. (1997) Ethanol inhibition of N-methyl-D-aspartate-activated current in mouse hippocampal neurones: whole-cell patch-clamp analysis. Br J Pharmacol 122: 1035–1042
Popp RL, Lovinger DM (2000) Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur J Pharmacol 394: 221–231
Priestley T, Kemp JA (1994) Kinetic study of the interactions between the glutamate and glycine recognition sites on the N-methyl-D aspartic acid receptor complex. Mol Pharmacol 46: 1191–1196
Rammes G, Mahal B, Putzke J et al. (2001) The anticraving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 40: 749–760
Riederer P, Lange KW, Kornhuber J et al. (1991) Pharmacotoxic psychosis after memantine in Parkinson’s disease. Lancet 338: 1022–1023
Ripley TL, Little HJ (1995) Effects of chronic ethanol withdrawal hyperexcitability of chronic treatment with a competitive N-methyl-D-aspartate receptor antagonist. J Pharmacol Exp Ther 272: 112–118
Ronald KM, Mirshahi T, Woodward JJ (2001) Ethanol inhibition of N-methyl-D-aspartate receptors is reduced by site-directed mutagenesis of a transmembrane domain phenylalanine residue. J Biol Chem 276: 44729–44735
Rosen MI, Persall HR, Kosten TR (1998) The effect of lamotrigine on naloxone-precipitated opiate withdrawal. Drug Alcohol Depend 52: 173–176
Rosetti ZL, Carboni S (1995) Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum. Eur J Pharmacol 283: 177–183
Rothman SM, Olney JW (1987) Excitotoxicity and the NMDA receptor. Trends Neurosci 10: 299–302
Schütz CG, Soyka M (2000) Dextromethorphan challenge in alcohol-dependent patients and controls. Arch Gen Psychiatry 57: 291–292
Seeburg PH (1993) The TINS/TiPS lecture. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci 16: 359–365
Spanagel R, Kornhuber J (1999) Glutamatrezeptorantagonisten und Alkoholabhängigkeit. Präklinische Befunde. Nervenarzt 70: 479–481
Spanagel R, Zieglgänsberger W, Hundt W (1996a). Acamprosate and alcohol. III. Effects on alcohol discrimination in the rat. Eur J Pharmacol 305: 51–56
Spanagel R, Hölter SM, Allingham K et al. (1996b) Acamprosate and alcohol. I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 305: 39–44
Spanagel R, Siegmund S, Cowen M et al. (2002) The neuronal nitric oxide synthase gene is critically involved in neurobehavioral effects of alcohol. J Neurosci 22: 8676–8683
Staley JK, Gottschalk PC, Petrakis IL et al. (2002) Assessment of cortical benzodiazepine-GABA-A receptors in recovering alcoholics over the first month of sobriety. Alcohol Clin Exp Res 26: 68A
Szatkowski M, Attwell D (1994) Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. Trends Neurosci 17: 359–365
Thomson AM, West DC, Lodge D (1985) An Nmethylaspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? Nature 313: 479–481
Traynelis SF, Burgess MF, Zheng F et al. (1998) Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. J Neurosci 18: 6163–6175
Trevisan L, Nammanworth S, Petrakis I et al. (1995) Cycloserine modulation of human ethanol intoxication: implications for NMDA receptor contributions to human ethanol intoxication. Alcohol Clin Exp Res 19: 4A
Tsai G (1998) Glutamatergic neurotransmission in alcoholism. J Biomed Sci 5: 309–320
Tsai G, Gastfriend DR, Coyle JT (1995) The glutamatergic basis of human alcoholism. Am J Psychiatry 152: 332–340
Vollenweider FX, Leenders KL, Øye I et al. (1997) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)-and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7: 25–38
Watson GB, Bolanowski MA, Baganoff MP et al. (1990) D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 510: 158–160
Wenk GL, Baker LM, Hauss-Wegrzyniak B et al. (1998) Novel glycine B antagonists show neuroprotective activity in vivo. Amino Acids 14: 223–226
Woodward JJ (2000) Ethanol and NMDA receptor signaling. Crit Rev Neurobiol 14: 69–89
Yamakura T, Mori H, Masaki H et al. (1993) Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. Neuro Report 4: 687–690
Literatur
Ammon S, Hofmann U, Griese EU et al. (1999) Pharmacokinetics of dihydrocodeine and its active metabolites after single and multiple oral dosing. Br J Clin Pharmacol 48: 317–322
Anggard E, Gunne LM, Homstrand J et al. (1975) Disposition of methadone in methadone maintenance. Clin Pharmacol Ther 17: 258–266
Ball J C, Ross A (1991) The effectiveness of methadone maintenance treatment. Springer, New York
Bodkin JA, Zomberg GL, Lukas SE et al. (1995) Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 15: 49–57
Boulton DW, Arnaud P, Devane CL et al. (2001) Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther 70: 48–57
Brooner RK, King VL, Kidorf M et al. (1997) Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 54: 71–80
BUB-Richtlinien (2003) Bekanntmachung des Bundesausschusses der Ärzte und Krankenkassen. Dtsch Ärztebl 100: B 132–134
Bundesärztekammer (2002) Richtlinien der Bundesärztekammer zur Durchführung der substitutionsgestützten Behandlung Opiatabhängiger. Dtsch Ärztebl 99: B-1218–1221
Darke S, Ross J (1997) Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug Alcohol Depend 48: 135–141
Davids E, Gastpar M (2004) Buprenorphine in the treatment of opioid dependence. Eur Neuropsychopharmacol 14: 209–216
Degwitz P (1996) Substitutionsbehandlung von Heroinabhängigen mit codeinhaltigen Präparaten — Ergebnisse einer Studie bei niedergelassenen Ärzten. Sucht 42: 257–259
Dole VP, Nyswander ME (1965) A medical treatment for diacethylmorphine (heroin) addiction. JAMA 193: 646–650
Eap CB, Cuendet C, Baumann P (1990) Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. Clin Pharmacol Ther 47: 338–346
Eap CB, Finkbeiner T, Gastpar M et al. (1996) Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. Eur J Clin Pharmacol 50: 385–389
Eap CB, Bourquin M, Martin J et al. (2000) Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend 61: 47–54
Eap CB, Buclin T, Baumann P (2002) Individual variability of the clinical pharmacokinetics of methadone. Clin Pharmacokinet 41: 1153–1193
Finkbeiner T, Gastpar M (1997) Der aktuelle Stand der Substitutionsbehandlung Drogenabhängiger. Nervenheilkunde 16: 215–221
Finn P, Wilcock K (1997) Levo-Alpha Acetyl Methadol (LAAM). Its advantages and drawbacks. J Subst Abuse Treat 14: 559–564
Geschwinde T (2003) Rauschdrogen, 5. Aufl. Springer, Berlin Heidelberg New York Tokyo
Ghodse H (2002) Drugs and addictive behaviour, 3rd edn. Cambridge University Press, Cambridge New York Melbourne
Goedecke H, Lander C, Menges K et al. (1994) Dihydrocodein/Codein — kein Mittel zur Substitution bei Drogenabhängigen. Bundesgesundheitsblatt 37: 207–212
Gossop M, Marsden J, Stewart D et al. (2003) The National Treatment Outcome Research Study (NTORS): 4–5 years follow-up results. Addiction 98: 291–303
Gourevitch MN, Hartel D, Tenore P et al. (1999) Three oral formulations of methadone: a clinical and pharmacodynamic comparison. J Subst Abuse Treat 17: 237–241
Inturrisi CE, Verebely K (1972) Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 13: 923–930
Kleber HD (1999) Opioids: detoxification. In: Galanter M, Kleber HD (eds) Textbook of substance abuse treatment, 2nd edn. American Psychiatric Press, Washington, pp 251–269
Krantz MJ, Lewkowiez L, Hays H et al. (2002) Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 137: 501–504
Krantz MJ, Kutinsky IB, Robertson AD et al. (2003) Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 23: 802–805
Krausz M, Degkwitz P, Kuhne A et al. (1998) Comorbidity of opiate dependence and mental disorders. Addict Behav 23: 767–783
Kristensen K, Blemmer T, Angelo HR et al. (1996) Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monit 18: 221–227
Lang F (1994) Zur Umstellung von Polamidon auf Methadon. Berliner Tinke Magazin 5: 4–6
Limbeek J V, Wouters L, Kaplan CD et al. (1992) Prevalence of psychopathology in drug-addicted Dutch. J Subst Abuse Treatment 9: 43–52
Mattick RP, Breen C, Kimber J et al. (2003) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. In: The Cochrane Library, Issue 1. Update Software, Oxford
Newman RG, Whitehill WB (1979) Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 2(8141): 485–488
Prognos (1998) Medikamentengestützte Rehabilitation i.v. Opiatabhängiger. Ministerium für Arbeit, Gesundheit und Soziales, NRW
Regier DA, Farmer ME, Rae DS et al. (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264: 2511–2518
Scherbaum N, Gastpar M (1991) Die Substitution mit Methadon als Therapieansatz in der Behandlung Opiatabhängiger. Nervenarzt 62: 529–535
Scherbaum N, Finkbeiner TH, Leifert K et al. (1996) The efficacy of l-methadone and racemic methadone in substitution treatment for opiate addicts — a double-blind comparison. Pharmacopsychiatry 29: 212–215
Scherbaum N, Blanke J, Wolstein J et al. (2003) Maternal health and drug abuse in Germany. ECCAS Monogr Series 3: 41–45
Schindler SD, Eder H, Ortner R et al. (2003) Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction 98: 103–110
Schmoldt A, von Meyer L, Riesselmann B et al. (2000) Drogenpolitik: Erobert Methadon die Drogenszene? Dtsch Ärztebl 97: A–1784
Sells SB, Simpson DD (1980) The case for drug abuse treatment effectiveness, based on the DARP research program. Br J Addict 75: 117–131
Senay EC (1999) Opioids: methadone maintenance. In: GALANTER M, KLEBER HD (eds) Textbook of substance abuse treatment, 2nd edn. American Psychiatric Press, Washington, pp 271–279
Simpson DD (1981) Treatment for drug abuse. Follow-up outcomes and length of time spent. Arch Gen Psychiatry 38: 875–880
Simpson DD, Savage LJ (1980) Drug abuse treatment readmissions and outcomes. Three-year follow-up of DARP patients. Arch Gen Psychiatry 37: 896–901
Simpson DD, Joe GW, Bracy SA (1982) Six-year follow-up of opioid addicts after admission to treatment. Arch Gen Psychiatry 39: 1318–1323
Stimson GV, Metrebian N (2003) Prescribing heroin. What is the evidence? York Publishing Services Ltd, York
Uchtenhagen A (2003) Substitution management in opioid dependence. J Neural Transm [Suppl 66]: 33–60
Wolff K, Hay AW, Raistrick D et al. (1993) Steady-state pharmacokinetics of methadone in opioid addicts. Eur J Clin Pharmacol 44: 189–194
Wolstein J, Rösinger C, Gastpar M (1998) Children and families in substance misuse. Curr Opin Psychiatry 11: 279–283
Literatur
Arzneimittelkommission der Deutschen Ärzteschaft (2001) Therapieempfehlungen Tabakabhängigkeit. Arzneiverordnungen in der Praxis, Sonderheft
Batra A (2000) Tabakabhängigkeit: biologische und psychosoziale Entstehungsbedingungen und Therapiemöglichkeiten. Steinkopff, Darmstadt
Batra A, Buchkremer G (Arbeitskreis Raucherentwöhnung) (Hrsg) (1997) Nichtraucher in 6 Wochen — Ein Selbsthilfeprogramm für alle, die das Rauchen aufgeben wollen. Preuss, Ratingen
Batra A, Buchkremer G (2004) Tabakabhängigkeit — Ein Therapeutenleitfaden. Kohlhammer, Stuttgart
Batra A, Fagerström KO (1997) New aspects of tobacco dependency and smoking cessation. Sucht 43: 277–282
Batra A, Lindinger P, Schütz C (2004) AWMFLeitlinien zur Behandlung der Tabakabhängigkeit. www.leitlinien.net
Blondal T, Franzon M, Westin A (1997) A doubleblind randomized trial of nicotine nasal spray as an aid in smoking cessation. Eur Respir J 10:1585–1590
Blondal T, Gudmundsson LJ, Olafsdottir I et al. (1999) Nicotine nasal spray with nicotine patch for smoking cessation: randomized trial with sic year follow up. Br Med J 318:285–289
Bohadana A, Nilsson F, Rasmussen T et al. (2000) Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation. Arch Intern Med 160: 3128–3134
Bollinger CT, Zellweger JP, Danielsson T et al. (2000) Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. Br Med J 321: 329–333
Cerny EH, Lévy R, Mauel J et al. (2002) Preclinical development of a vaccine against smoking. Oncology 25: 406–411
Choi J, Dresler CM, Norton M et al. (2003) Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 5: 635–644
Dale L, Anthenelli R, Despres JP et al. (2004) Effects of Rimonabant in the reduction of major cardiovasular risk factors: results from the STRATUS-US Trial (Smoking cessation in smokers motivated to quit) and the RIO-LIPIDS Trial (weight reducing and metabolic effects in overweight/obese patients with dyslipidaemia). American College of Cardiology (ACC), 53th Annual Scientific Session, March 3–10, 2004, New Orleans
DHS (Deutsche Hauptstelle für Suchtfragen) (Hrsg) (2003) Jahrbuch Sucht 04. Neuland, Geesthacht
Eliasson B, Hjalmarson A, Kruse E et al. (2001) Effect of smoking reduction and cessation on cardiovascular risk factors. Nicotine Tob Res 3: 249–255
Fagerström KO (2003) Clinical treatment of tobacco dependence: the endurance of pharmacologic efficacy. J Clin Psychiatry Monogr 18(1): 35–40
Fiore MC, Bailey WC, Cohen SJ et al. (2000) Treating tobacco use and dependence. Clinical Practice Guideline. U.S. Department of Health and Human Services, Public Health Service, Rockville, MD
Garvey AJ, Kinnunen T, Nordstrom BL (2000) Effects of nicotine gum dose by level of nicotine dependence. Nicotine Tob Res 2:53–63
George TP, O’Malley SS (2004) Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 25(1): 42–48
Gourlay SG, Stead LF, Benowitz NL (2001) Clonidine for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2. Update Software, Oxford
Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A (1999) Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 159: 2033–2038
Hays JT, Hurt RD, Rigotti NA et al. (2001) Sustained-release Bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med 135: 423–433
Hieda Y, Keyler DE, Ennifar S et al. (2000) Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 22:809–819
Hjalmarson A, Franzon M, Westin A et al. (1994) Effect of nicotine nasal spray on smoking cessation: a randomised, placebo-controlled, double-blind study. Arch Intern Med 154:2567–2572
Hjalmarson A, Nilsson F, Sjöström L et al. (1997) The nicotine inhaler in smoking cessation. Arch Intern Med 157: 1721–1728
Hughes JR, Shiffman S, Callas P et al. (2003) A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tobacco Control 12: 21–27
Hurt RD, Offord KP, Croghan IT et al. (1998) Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. Psychopharmacology 140: 98–104
Hurt RD, Sachs D, Glover ED (1997) A comparison of sustained-release Bupropion and placebo for smoking cessation. N Engl J Med 337:1195–202
John U, Hanke M (2002) Tobacco smoking-and alcohol drinking-attributable cancer mortality in Germany. Eur J Cancer Prev 11: 11–17
Johnston JA, Ascher J, Leadbetter R et al. (2002) Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation. Drugs 62[Suppl 2]: 11–24
Jorenby DE, Leischow SJ, Nides MA et al. (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340: 685–689
Lancaster T, Stead LF (2003) Self-help interventions for smoking cessation. (Cochrane Review). In: The Cochrane Library, Issue 2. Update Software, Oxford
Mcrobbie H, Hajek P (2001) Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction 96: 1547–1551
Molander L, Lunell E (2001) Pharmacokinetic investigation of a nicotine sublingual tablet. Eur J Clin Pharmacol 56: 813–819
Pentel P, Malin D (2002) A vaccine for nicotine dependence: targeting the drug rather than the brain. Respiration 69: 193–197
Schneider NG, Olmstead R, Mody FV et al. (1995) Efficiency of a nicotine nasal spray in smoking cessation: a placebo controlled, double-blind trial. Addiction 90: 1671–1682
Schneider NG, Olmstead RE, Franzon MA et al. (2001) The nicotine inhaler. Clinical pharmacokinetics and comparsion with other nicotine treatments. Clin Pharmacokinet 40(9):661–684
Shiffman S, Dresler CM, Hajek P et al. (2002) Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 162: 1267–1276
Silagy C, Lancaster T, Staed L et al. (2003) Nicotine replacement therapy for smoking cessation (Cochrane Review) In: The Cochrane Library, Issue 2, Update Software, Oxford
Stead LF, Lancaster T (2003) Group behaviour therapy programmes for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2. Update Software, Oxford
Sutherland G, Stapleton JA, Russell MAH et al. (1992) Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 340: 324–329
Tønnesen P, Nørregaard J, Mikkelsen K et al. (1993) Double-blind trial of a nicotine inhaler for smoking cessation. JAMA 269: 1268–1271
Tønnesen P, Paoletti P, Gustavsson G et al. (1999) Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Eur Respir J 13: 238–246
Tonstad S (2002) Use of sustained-release bupropion in specific patient populations for smoking cessation. Drugs 62[Suppl 2]: 37–43
White AR, Rampes H, Erns E (2003) Acupuncture for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2. Update Software, Oxford
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag/Wien
About this chapter
Cite this chapter
Böning, J. et al. (2006). Suchttherapeutika zur Sucht. In: Riederer, P., Laux, G. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/3-211-37774-3_4
Download citation
DOI: https://doi.org/10.1007/3-211-37774-3_4
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-22956-9
Online ISBN: 978-3-211-37774-1
eBook Packages: Medicine (German Language)